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NEW STATISTICAL METHODS FOR THE EVALUATION OF 
EFFECTIVENESS AND SAFETY OF A MEDICAL INTERVENTION IN USING 
OBSERVATIONAL DATA 
 
 
Observational studies offer unique advantages over randomized clinical trials 
(RCTs) in many situations where RCTs are not feasible or suffer from major 
limitations such as insufficient sample sizes and narrowly focused populations.   
Because observational data are relatively easy and inexpensive to access, and 
contain rich and comprehensive demographic and medical information on large and 
representative populations, they have played a major role in the assessment of the 
effectiveness and safety of medical interventions. However, observational data also 
have the challenges of higher rates of missing data and the confounding effect.  
My proposal is on the development of three statistical methods to address 
these challenges. The first method is on the refinement and extension of a multiply-
robust (MR) estimation procedure that simultaneously accounts for the confounding 
effect and missing covariate process, where we derived the asymptotic variance 
estimator and extended the method to the scenario where the missing covariate is 
continuous.  The second method focuses on the improvement of estimation precision 
in an RCT by a historical control cohort. This was achieved through augmenting the 
conventional effect estimator with an extra mean zero (approximately) term 
correlated with the conventional effect estimator. In the third method, we calibrated 
the hidden database bias of an electronic medical records database and utilized an 
empirical Bayes method to improve the accuracy of the estimation of the risk of acute 
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myocardial infarction associated with a drug by borrowing information from other 
drugs. 
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CHAPTER 1. INTRODUCTION 
 Interest in the use of electronic healthcare databases for comparative effectiveness 
and safety research is increasing [1-4]; these data are readily available, relatively 
inexpensive to access, and contain rich and comprehensive demographic and medical 
information on large, representative populations. In many scenarios in which clinical 
trials are not feasible due to either ethical or practical reasons, these observational 
databases provide valuable opportunities for the effectiveness and safety research. 
My dissertation contains three related topics of new statistical methods in using 
observational data.  
 In Chapter 2, I focus on a multiple robust (MR) method for missing data in 
observational study. In Chapter 3, I plan to use the historical data to improve the 
precision of estimation of the treatment effect from a small randomized control trial 
(RCT). In Chapter 4, by incorporating the existing knowledge, I utilize an empirical 
Bayes method for the evaluation of the drug safety from the observational data 
(electronic medical records (EMR) database).  
  
 2 
1.1 A Multiply-robust Approach for Missing Data in Observational Study 
 Confounding bias and missing data are two major barriers to valid comparative 
effectiveness studies using observational electronic healthcare data. Each respective 
problem has been extensively studied. However, a unified approach to handle both issues 
simultaneously would be very helpful for observational studies with missing data 
problem. Multiply-robust (MR) methodology, which builds upon the well-established 
doubly-robust theory (proposed by Lingling Li, Williamson[5] independently), is such a 
remedy. The MR method is 4-fold robust in that it is consistent and asymptotic normal if 
one of four sets of modeling assumptions holds. However, the asymptotic variance of MR 
estimator hasn’t been explored. In this chapter, we develop the asymptotic variance of 
MR estimator and extend the method from a missing binary covariate scenario to a 
missing continuous covariate scenario. We evaluate the performance of the MR estimate 
with a binary or continuous missing covariate and its asymptotic variance via a 
simulation study. The simulation study uses synthetic datasets to evaluate the 
performance of the MR method under a variety of settings, which cover most of the 
scenarios in the practical problems.  
 
1.2 An Inverse Probability Weighting Approach for Historical Control Augmented 
Randomized Clinical Trials 
 The randomized control trial (RCT) is often considered as the gold standard for 
evaluating the effectiveness or safety of various types of medical interventions. While in 
the practical world, there might be difficulty in getting enough patients in to RCT 
especially for rare diseases. The remedy for this situation is to borrow information from 
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similar historical studies. To combine the historical data in to RCT, people now are 
mainly using Bayesian approach such as power prior and Bayesian hierarchical model. In 
this dissertation, we explored a frequentist approaching utilizing inverse probability 
weighting method to adjust for the difference in covariates between RCT and historical 
data. The IPW estimate could bring us more efficiency while still keep the unbiased 
property. We carried out a simulation to evaluate its performance compared with the 
estimate from RCT only.  
 
1.3 The Associations of Drugs with Acute Myocardial Infarction: Bias Correction, Global 
Profiling and Inference on Individual Drug 
 We address two issues in drug-outcome association studies. First, it has been 
recognized that electronic health records databases may have database biases, for 
example, failure or incomplete capture of exposure and covariates, such that confounding 
cannot be fully controlled. In addition, there may be biases due to model 
misspecification. Consequently, risk estimates may be biased, resulting in the misguided 
assessment of the strength and direction of drug-outcome associations. Second, the 
distribution of the risk measures of relevant drugs on market for a given outcome not 
only characterizes the global profile of drug-outcome associations, but also can be used to 
improve the accuracy of the association estimate for future drugs through Bayes 
inference. Using acute myocardial infarction (AMI) as an example, we illustrate how the 
first issue can be addressed by calibrating the risk measures through drugs known to have 
no association with AMI in a population-level electronic medical records database, the 
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Indiana Network for Patient Care (INPC). We then employ an empirical Bayes approach 
to address the second issue.  
 The study shows that without the bias correction, 68.1%, 11.9% and 2.3% of the 
drugs included have a risk ratio for AMI greater than 1, 1.5 and 2, respectively. After the 
bias correction, the proportions become 51.5%, 7.0% and 1.4%, respectively. Using the 
empirical Bayes method, we gain 45% (without bias correction) and 52% (with bias 
correction) precision for the estimation of the risk ratio of a hypothetical new drug. Our 
approach serves as a general strategy for pharmaco-epidemiology studies for either an 
individual drug-outcome pair or multiple drug-outcome pairs. 
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CHAPTER 2. A MULTIPLY-ROBUST APPROACH FOR MISSING DATA IN 
OBSERVATIONAL STUDY 
2.1 Background 
Since observational databases are collected primarily for non-research purposes, 
they might have several limitations for evaluation of effectiveness and precision. First of 
all, confounding bias [6] exists and needs to be adjusted for when they are used to derive 
causal inference on treatments or interventions. Moreover, missing confounder and 
outcome data commonly occur due to various reasons [7].  Each respective problem has 
been extensively studied. Recently, there exists the multiply-robust (MR) approach [5], 
for missing outcome and confounder data in comparative effectiveness studies using 
observational databases. The method applies the double-robust (DR) method in a nested 
fashion to handle confounding bias and missing confounder data (either binary or 
continuous) in a unified manner. It is 4-fold robust [8] that it is consistent if one of four 
sets of modeling assumptions holds. [9-14] 
 In this chapter, we introduce the MR method and focus on the asymptotic 
characteristics of the MR estimates. In the Methods section, we introduce our notation, 
review the existing DR methods for causal inference and missing data models [12, 13], 
and present the MR method in dealing with either a binary or a continuous missing 
variables. For the purpose of comparison, we also introduce two non-MR competitors. 
Then we induce the asymptotic variance estimate of MR estimate using Taylor 
expansion. Next in the Simulation section, we describe the simulation studies to evaluate 
and compare the performance of the MR method with the two alternatives. We end with 
Discussion. 
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2.2 Methods 
2.2.1 Notation 
 Let ?̅? = {𝐎𝑖 = (𝑌𝑖, 𝐴𝑖 , 𝐗𝑖, 𝑅𝑖, 𝑅𝑖𝑍𝑖), 𝑖 = 1,… , 𝑛} denote 𝑛 copies of independently 
and identically distributed data, where 𝑌𝑖 denotes subject 𝑖’s outcome (continuous or 
binary), 𝐴𝑖 denotes the binary treatment indicator (1 for intervention arm and 0 for 
control arm), 𝑋𝑖 denotes a p-dimensional vector of potential confounders that are always 
observed, 𝑍𝑖  denotes the confounder (continuous or binary) that is subject to missingness, 
and 𝑅𝑖 denotes the dichotomous missing indicator for 𝑍𝑖, i.e., 𝑍𝑖 is observed if and only if 
𝑅𝑖 = 1. Further, let (𝑌𝑖,1, 𝑌𝑖,0) denote subject i’s two potential outcomes for treatment and 
no treatment respectively. The parameter of interest is the average treatment effect, i.e., 
𝜓 ≡ 𝐸[𝑌𝑖,1] − 𝐸[𝑌𝑖,0]. Let 𝜓0 denote the true value for 𝜓. The results below can be easily 
extended to other effect measures such as the causal relative risk 𝐸[𝑌𝑖,1]/𝐸[𝑌𝑖,0]  for 
binary outcomes.  
 Throughout the paper, we impose the following assumptions. 
Assumption 1. Consistency: 𝑌 = 𝑌𝐴. 
Assumption 2. Positivity: Pr(𝐴 = 1|𝑋, 𝑍) > 0 with probability 1. 
Assumption 3. No unmeasured confounders (NUC): (𝑌1, 𝑌0) are conditionally 
independent of 𝐴 given (𝑋, 𝑍). 
Assumption 4. Missing at random (MAR): Pr(𝑅 = 1|𝑌, 𝐴, 𝑋, 𝑍) = Pr(𝑅 = 1|𝑌, 𝐴, 𝑋) and 
Pr(𝑅 = 1|𝑌, 𝐴, 𝑋) > 0 with probability 1. 
 Let 𝑏(𝐴, 𝑋, 𝑍) denote 𝐸[𝑌|𝐴, 𝑋, 𝑍], the outcome regression (OR) function; and let 
𝑒(𝑋, 𝑍) denote Pr(𝐴 = 1|𝑋, 𝑍), the propensity score (PS) function which is defined as 
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the conditional probability of receiving treatment given the confounders. Under NUC, 
(𝑌1, 𝑌0) ⊥ 𝐴|𝑒(𝑋, 𝑍) [11]. Let 𝜋(𝑌, 𝐴, 𝑋) denote Pr(𝑅 = 1|𝑌, 𝐴, 𝑋, 𝑍) = Pr (𝑅 =
1|𝑌, 𝐴, 𝑋) under MAR, the conditional probability of observing complete data. When 𝑍 is 
binary, let 𝜛(𝑌, 𝐴, 𝑋) denote Pr(𝑍 = 1|𝑌, 𝐴, 𝑋) = Pr (𝑍 = 1|𝑅 = 1, 𝑌, 𝐴, 𝑋) under MAR, 
the conditional probability of having 𝑍 = 1 given (𝑌, 𝐴, 𝑋) among subjects with 
complete data. When 𝑍 is continuous, let 𝜛(𝑌, 𝐴, 𝑋) denote E(𝑍|𝑌, 𝐴, 𝑋) = E(𝑍|𝑅 =
1, 𝑌, 𝐴, 𝑋) under MAR, the conditional expectation of 𝑍 given (𝑌, 𝐴, 𝑋) among subjects 
with complete data. Let 𝑃𝑛{ℎ(𝑂)} =
1
𝑛
∑ ℎ(𝑂)𝑛𝑖=1  denote the sample mean of any given 
function ℎ(∙).   
2.2.2 DR estimation in causal inference models 
 We first consider a hypothetical causal inference model in which complete 
confounder data is observed for all study subjects, i.e., data is denoted by ?̅?𝐹 =
{𝐎𝑖
𝐹 = (𝑌𝑖, 𝐴𝑖 , 𝐗𝑖, 𝑍𝑖), 𝑖 = 1,… , 𝑛}. Under the NUC assumption, there are in general two 
classes of methods that are commonly used to adjust for confounding, one based on the 
OR model, the other on the PS model. The OR-based analysis depends on the OR 
function 𝑏(𝐴, 𝐗, 𝑍). A parametric working model, 𝑏(𝐴, 𝐗, 𝑍; 𝜂), is imposed for 𝑏(𝐴, 𝐗, 𝑍) 
and fitted to data {(𝑌𝑖, 𝐴𝑖 , 𝐗𝑖, 𝑍𝑖), 𝑖 = 1,… , 𝑛} to obtain the maximum likelihood estimator 
of 𝜂, ?̃?.  Then the OR-based estimator of 𝜓, ?̃?𝑂𝑅, can be calculated as Ρ𝑛{𝑏(𝐴 =
1, 𝐗, 𝑍; ?̃?)} − Ρ𝑛{𝑏(𝐴 = 0, 𝐗, 𝑍; ?̃?)}. The OR-based estimator ?̃?𝑂𝑅 is a consistent 
estimator of 𝜓 if the imposed parametric working model 𝑏(𝐴, 𝐗, 𝑍; 𝜂) is correct. Standard 
regression methods such as linear and logistic regressions belong to this class. The PS-
based analysis depends on the PS function 𝑒(𝐗, 𝑍). A parametric working model 
𝑒(𝐗, 𝑍; 𝛼) (e.g., a logistic regression model) is imposed for 𝑒(𝐗, 𝑍) and fitted to data 
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{(𝐴𝑖, 𝐗𝑖, 𝑍𝑖), 𝑖 = 1, … , 𝑛} to obtain the maximum likelihood estimator of 𝛼, ?̃?, and the 
estimated PSs {?̃?𝑖 ≡ 𝑒(𝐗𝑖, 𝑍𝑖; ?̃?), 𝑖 = 1,… , 𝑛}. PSs can be used in different ways: for 
matching [11], stratification [10], regression adjustment [9], and weighting [9, 12, 13]. 
For instance, a PS weighting estimator 
 ?̃?𝐼𝑃𝑊 ≡ (𝑃𝑛 {
𝐼(𝐴=1)
𝑒(𝐗,𝑍;?̃?)
})
−1
Ρ𝑛 {
𝐼(𝐴=1)
𝑒(𝐗,𝑍;?̃?)
𝑌} − (𝑃𝑛 {
𝐼(𝐴=0)
1−𝑒(𝐗,𝑍;?̃?)
})
−1
Ρ𝑛 {
𝐼(𝐴=0)
1−𝑒(𝐗,𝑍;?̃?)
𝑌}. The 
validity of the PS-based methods requires the PS model is correctly specified.  
 The two classes of approaches have their own respective merits.  Nevertheless, 
the OR-based methods require the OR function 𝑏(𝐴, 𝐗, 𝑍) to be correctly specified, and 
the PS-based methods require the PS function 𝑒(𝐗, 𝑍) to be correctly specified.  Model 
misspecification remains a threat to the validity of analyses results no matter which 
method is chosen.  The DR method combines both OR and PS models in a fashion that 
gives valid inference if either model is correct, but not necessarily both [14]. Thus, it 
offers dual protection against model misspecifications. Furthermore, even when both the 
OR and PS models are misspecified (which is not uncommon in practice with many 
covariates and complex function forms), if either model is nearly correct, the DR 
estimator, according to theory and simulation results [14, 15], substantially reduces the 
bias. Thus, this method offers the analyst two chances to make nearly correct inference 
on the parameter of interest.  Specifically, the DR estimator of 𝜓, 𝜓𝐷𝑅(?̅?
𝐹; 𝛼, 𝜂), is 
obtained by solving the estimating equation below 
 Ρ𝑛{𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) − 𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂)} − 𝜓 = 0, (1)  
where 
𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) =
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
𝑌 − (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
− 1)𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂), (2)  
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𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂) =
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
𝑌
− (
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
− 1) 𝑏(𝐴 = 0, 𝐗, 𝑍; 𝜂). 
(3)  
Let ?̃?𝐷𝑅 denote 𝜓𝐷𝑅(?̅?
𝐹; ?̃?, ?̃?). It is known that ?̃?𝐷𝑅 is a consistent and asymptotically 
normal (CAN) estimator of 𝜓 if either of the OR and PS working models is correct, but 
not necessarily both [14].  
2.2.3 DR estimation in missing data 
 The DR method in missing data models shares the same heuristic ideas as that in 
causal inference models. In fact, the causal inference models can be conceptually viewed 
as missing data models. The average treatment effect 𝜓 is the difference between the 
marginal means of the two potential outcomes. For the marginal mean 𝐸[𝑌𝑎], 𝑎 ∈ {0,1}, 
the potential outcome 𝑌𝑎 is observed only for a subset of subjects with 𝐴𝑖 = 𝑎. Thus, in 
this conceptual “missing data” model, the potential outcome 𝑌𝑎 is the component that is 
subject to missingness and the dummy variable 𝐼(𝐴𝑖 = 𝑎) is the “missing-data indicator”. 
 Consider a general missing data model in which 𝑅𝑖 denotes subject i’s missing 
indicator, 𝐎𝑖
𝐹 denotes the full data and 𝐎𝑖 denotes the observed data, and 𝜃 = 𝐸[ℎ(𝐎𝑖
𝐹)] 
denotes the parameter of interest, the marginal mean of a known function ℎ(∙). We 
assume the MAR assumption holds, i.e., Pr(𝑅 = 1|𝐎𝑖
𝐹) = Pr(𝑅 = 1|𝐎𝑖), which is 
denoted as 𝜋(𝐎𝑖).  
 Based on the DR theory for missing data, it can be shown that the DR estimator of 
𝜃, 𝜃𝐷𝑅(?̅? = (𝐎1, … , 𝐎𝑛)), is obtained by solving the estimating equation below. 
Ρ𝑛 {
𝑅
𝜋(𝐎𝑖)
ℎ(𝐎𝑖
𝐹) − (
𝑅
𝜋(𝐎𝑖)
− 1)𝐸[ℎ(𝐎𝑖
𝐹)|𝑅 = 1,𝐎𝑖]} − 𝜃 = 0. (4)  
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Heuristically, this approach weights subjects who have complete data by 𝜋−1(𝐎𝑖) to 
remove the selection bias due to missing data, and adds an augmentation term 
(
𝑅
𝜋(𝐎𝑖)
− 1)𝐸[ℎ(𝐎𝑖
𝐹)|𝑅 = 1,𝐎𝑖] to increase efficiency and provide the double-robustness 
property. 
2.2.4 MR estimation to handle missing confounder in causal inference models 
 Next, we introduce the MR estimator of 𝜓, ?̂?𝑀𝑅, that depends on the observed 
data ?̅? only and has a multiple-robustness bias property that will be discussed later this 
section. 
2.2.4.1 The MR estimator 
 The MR method uses DR estimation in causal inference and missing data models 
in a nested fashion, and constructs the estimating function for 𝜓𝑀𝑅 in two stages. The 
first stage is DR estimation in a hypothetical causal inference model with complete 
confounder data ?̅?𝐹 = {𝐎𝑖
𝐹 = (𝑌𝑖, 𝐴𝑖 , 𝐗𝑖, 𝑍𝑖), 𝑖 = 1,… , 𝑛}. Note that the estimating 
function for 𝜓𝐷𝑅(?̅?
𝐹; 𝛼, 𝜂) is {𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) − 𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂) − 𝜓} with 𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) and 
𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂) defined in Eqs. (2) and (3) respectively. This estimating function depends 
on the confounder Z, which, in the observed data ?̅? = {𝐎𝑖 = (𝑌𝑖, 𝐴𝑖, 𝐗𝑖, 𝑅𝑖, 𝑅𝑖𝑍𝑖), 𝑖 =
1, . , 𝑛}, is available only for the subset of subjects with 𝑅𝑖 = 1. To address this issue, in 
the second stage, we apply DR estimation to estimate 𝜃 = 𝐸[ℎ∗(𝐎𝑖
𝐹; 𝛼, 𝜂)] where 
ℎ∗(𝐎𝑖
𝐹; 𝛼, 𝜂) ≡ 𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) − 𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂). Let 𝜋(𝑌, 𝐴, 𝐗; 𝛾) denote the imposed 
parametric working model for 𝜋(𝑌, 𝐴, 𝐗) ≡ Pr(𝑅 = 1|𝑌, 𝐴, 𝐗, 𝑍) = Pr (𝑅 = 1|𝑌, 𝐴, 𝐗) 
under MAR, and 𝜛(𝑌, 𝐴, 𝐗; 𝜔) denote the imposed parametric working model for 
𝜛(𝑌, 𝐴, 𝐗) ≡ Pr(𝑍 = 1|𝑌, 𝐴, 𝐗) = Pr (𝑍 = 1|𝑅 = 1, 𝑌, 𝐴, 𝐗) under MAR. Then by Eq. 
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(4), the estimating function for 𝜃𝐷𝑅(?̅?, 𝛼, 𝜂, 𝛾, 𝜔) =
𝑅
𝜋(𝑌,𝐴,𝐗;𝛾)
ℎ∗(𝐎𝐹; 𝛼, 𝜂) −
(
𝑅
𝜋(𝑌,𝐴,𝐗;𝛾)
− 1)𝐸[ℎ∗(𝐎𝐹; 𝛼, 𝜂)|𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔)] − 𝜃. After plugging in the expressions 
of 𝜇1
𝐹(𝐎𝐹; 𝛼, 𝜂) and 𝜇0
𝐹(𝐎𝐹; 𝛼, 𝜂), we obtain the estimating function for 
𝜓𝑀𝑅(?̅?; 𝛼, 𝜂, 𝛾, 𝜔) as 
𝐼𝐹𝑀𝑅(?̅?; 𝛼, 𝜂, 𝛾, 𝜔, 𝜓) 
≡
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
×
{
 
 
 
 (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
𝑌 − (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
− 1)𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂)) − 
(
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
𝑌 − (
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
− 1)𝑏(𝐴 = 0, 𝐗, 𝑍; 𝜂))
}
 
 
 
 
 
−(
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
− 1) 
× 𝐸
[
 
 
 
 
{
 
 
 
 (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
𝑌 − (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼)
− 1) 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂)) −
(
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
𝑌 − (
𝐼(𝐴 = 0)
1 − 𝑒(𝐗, 𝑍; 𝛼)
− 1) 𝑏(𝐴 = 0, 𝐗, 𝑍; 𝜂))
}
 
 
 
 
|
|𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔
]
 
 
 
 
 
−𝜓. 
 It is obvious that 𝐼𝐹𝑀𝑅(?̅?; 𝛼, 𝜂, 𝛾, 𝜔, 𝜓) depends on observed data ?̅?, as well as 4 
nuisance parameters (𝛼, 𝜂, 𝛾, 𝜔). The MLE of 𝛾, 𝛾, can be easily obtained by fitting the 
imposed parametric model 𝜋(𝑌, 𝐴, 𝐗; 𝛾) for Pr (𝑅𝑖 = 1|𝑌𝑖, 𝐴𝑖, 𝐗𝑖) on the observed data 
{(𝑅𝑖, 𝑌𝑖, 𝐴𝑖 , 𝐗𝑖), 𝑖 = 1,…𝑛}. The most commonly used working models for 𝜋(𝑌, 𝐴, 𝐗) are 
logistic regression models.  
 When Z is binary, for any given function ℎ(𝑌, 𝐴, 𝐗, 𝑍),  
𝐸[ℎ(𝑌, 𝐴, 𝐗, 𝑍)|𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔] 
= ℎ(𝑌, 𝐴, 𝐗, 𝑍 = 1)𝜛(𝑌, 𝐴, 𝐗; 𝜔) + ℎ(𝑌, 𝐴, 𝐗, 𝑍 = 0)(1 − 𝜛(𝑌, 𝐴, 𝐗; 𝜔)). 
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The MLE of 𝜔, ?̂?, can be obtained by fitting the imposed parametric model 
𝜛(𝑌, 𝐴, 𝐗; 𝜔) for 𝑃𝑟(𝑍𝑖 = 1|𝑅𝑖 = 1, 𝑌𝑖, 𝐴𝑖, 𝐗𝑖) on the observed data {(𝑍𝑖, 𝑌𝑖, 𝐴𝑖 , 𝐗𝑖)|𝑖 =
1, …𝑛 𝑎𝑛𝑑 𝑅𝑖 = 1} among the subset of complete cases.  
 When Z is continuous,  
𝐸[ℎ(𝑌, 𝐴, 𝐗, 𝑍)|𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔] ≅ ℎ(𝑌, 𝐴, 𝐗, ?̂?). 
Since 𝑍 is continuous, the expectation is obtained through integration while could be 
computationally demanding. Here we use ?̂?, the MLE of 𝜔, obtained by fitting the 
imposed parametric model 𝜛(𝑌, 𝐴, 𝐗; 𝜔) for 𝐸(𝑍𝑖|𝑅𝑖 = 1, 𝑌𝑖 , 𝐴𝑖 , 𝐗𝑖) on the observed data 
{(𝑍𝑖, 𝑌𝑖, 𝐴𝑖, 𝐗𝑖)|𝑖 = 1,…𝑛 𝑎𝑛𝑑 𝑅𝑖 = 1} among the subset of complete cases, to 
approximate the expectation of ℎ. 
 The estimation of 𝛼 and 𝜂 is less straightforward since their MLEs depend on 
{𝑍𝑖, 𝑖 = 1,… , 𝑛}, which is only partially observed in ?̅?. For instance, ?̂? is typically 
obtained by solving P𝑛{𝑆𝛼(𝐴, 𝐗, 𝑍; 𝛼)} = 0 where 𝑆𝛼(𝐴, 𝐗, 𝑍; 𝛼) is the score function for 
𝛼 and equals (𝐴 − 𝑒(𝐗, 𝑍; 𝛼))(1, 𝑋𝑇 , 𝑍)𝑇 with a logistic working model 
𝑙𝑜𝑔𝑖𝑡(𝑒(𝐗, 𝑍; 𝛼)) = (1, 𝐗𝑇 , 𝑍)𝛼. But in ?̅?, 𝑍𝑖 is observed if and only if 𝑅𝑖 = 1.  To 
address this issue, we apply DR estimation to the estimating function of ?̂?, and obtain a 
DR estimator of 𝛼, ?̂?𝐷(𝛾, ?̂?), by solving the estimating equation below 
P𝑛 {
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
𝑆𝛼(𝐴, 𝐗, 𝑍; 𝛼) − (
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
− 1) ×
𝐸[𝑆𝛼(𝐴, 𝐗, 𝑍; 𝛼)|𝑅 = 1, 𝑌, 𝐴, 𝐗; ?̂?]
} = 0 (5)  
Suppose 𝛼0 denotes the solution to 𝐸[𝑆𝛼(𝐴, 𝐗, 𝑍; 𝛼)] = 0.  The estimator ?̂?𝐷(𝛾, ?̂?) is DR 
in the sense that it is a consistent estimator of 𝛼0 if either the working model 𝜋(𝑌, 𝐴, 𝐗; 𝛾) 
or the working model 𝜛(𝑌, 𝐴, 𝐗; 𝜔) is correctly specified, but not necessarily both. 
Similarly, we construct the DR estimator of 𝜂, ?̂?𝐷(?̂?, ?̂?), by applying DR estimation to 
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the estimating function of ?̂?. Specifically, ?̂?𝐷(?̂?, ?̂?) is obtained by solving the estimating 
equation below 
Ρ𝑛 {
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍; 𝜂) − (
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
− 1)
× 𝐸[𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍; 𝜂)|𝑅 = 1, 𝑌, 𝐴, 𝐗; ?̂?]
} = 0, (6)  
where 𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍; 𝜂) is the score function for 𝜂.    
 Finally, we have the MR estimator 
?̂?𝑀𝑅 ≡ 𝜓𝑀𝑅(?̅?; ?̂?𝐷(?̂?, ?̂?), ?̂?𝐷(?̂?, ?̂?), 𝛾, ?̂?). 
2.2.4.2 Asymptotic variance of ?̂?𝑀𝑅 
 The MR estimator ?̂?𝑀𝑅 depends on the following four working models:  
 Model (i): 𝑏(𝐴, 𝐗, 𝑍; 𝜂) for the OR function 𝐸[𝑌|𝐴, 𝐗, 𝑍]  
 Model (ii): 𝑒(𝐗, 𝑍; 𝛼) for the PS function Pr(𝐴 = 1|𝐗, 𝑍) 
 Model (iii):  𝜋(𝑌, 𝐴, 𝐗; 𝛾) for the missing indicator function Pr(𝑅 = 1|𝑌, 𝐴, 𝐗)  
 Model (iv):  𝜛(𝑌, 𝐴, 𝐗; 𝜔) for the conditional mean function Pr(𝑍 = 1|𝑅 =
1, 𝑌, 𝐴, 𝐗) (binary Z) or 𝐸(𝑍|𝑅 = 1, 𝑌, 𝐴, 𝐗) (continuous Z) 
 Under mild regularity conditions [16] and Assumptions 1-4, ?̂?𝑀𝑅 is a CAN 
estimator of 𝜓0 if at least one of the following four conditions holds:  
 Condition 1: working model (i) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] and model (iii) for Pr (𝑅 =
1|𝑌, 𝐴, 𝐗) are correct 
 Condition 2: working model (ii) for Pr(𝐴 = 1|𝐗, 𝑍) and model (iii) for Pr (𝑅 =
1|𝑌, 𝐴, 𝐗) are correct 
 Condition 3: working model (i) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] and model (iv) for Pr (𝑍 = 1|𝑅 =
1, 𝑌, 𝐴, 𝐗) (binary Z) or 𝐸(𝑍|𝑅 = 1, 𝑌, 𝐴, 𝐗) (continuous Z) are correct 
 14 
 Condition 4: working model (ii) for Pr(𝐴 = 1|𝐗, 𝑍) and model (iv) for 
Pr(𝑍 = 1|𝑅 = 1, 𝑌, 𝐴, 𝑿) (binary Z) or 𝐸(𝑍|𝑅 = 1, 𝑌, 𝐴, 𝐗) (continuous Z) are 
correct.    
 We provide the proof of asymptotic normality and consistency, the induction of 
the asymptotic variance 𝑉𝑎𝑟(?̂?𝑀𝑅) in Appendix A. More details about the variance 
formula for binary/continuous missing covariate 𝑍 are elaborated in Appendix B An 
empirical VARIANCE ESTIMATe of ?̂?𝑎 and Appendix C An empirical VARIANCE 
ESTIMATe of ?̂?𝑎.  
2.2.5 Two alternative approaches 
 For the purpose of comparison, we introduce two alternative approaches. 
2.2.5.1 The complete-case approach 
 The complete-case approach is the simplest and possibly the most commonly used 
approach to deal with missing data. It conducts standard analyses among complete cases, 
i.e., the subset of subjects with complete data on relevant variables. In our setting, the 
complete-case approach fits the imposed working model 𝑏(𝐴, 𝐗, 𝑍; 𝜂) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] 
among the complete cases  (𝑅 = 1) to obtains an MLE of 𝜂, ?̌?; uses the fitted model to 
predict outcome means 𝑏(𝐴 = 1, 𝐗, 𝑍; ?̌?) and 𝑏(𝐴 = 0, 𝐗, 𝑍; ?̌?) for each complete case; 
and finally estimates 𝜓 by taking the sample average of the mean difference among 
complete cases.  Specifically, 
?̂?𝐶𝐶 = (Ρ𝑛{𝐼(𝑅 = 1)})
−1Ρ𝑛{𝐼(𝑅 = 1)[𝑏(𝐴 = 1, 𝐗, 𝑍; ?̌?) − 𝑏(𝐴 = 0, 𝐗, 𝑍; ?̌?)]}. 
Even when 1) the working model 𝑏(𝐴, 𝐗, 𝑍; 𝜂) is correct in that 𝐸[𝑌|𝐴, 𝐗, 𝑍] =
𝑏(𝐴, 𝐗, 𝑍; 𝜂0), and 2) the MAR assumption holds, the complete-case approach may still 
be biased as 𝐸[𝑌|𝐴, 𝐗, 𝑍] may differ from 𝐸[𝑌|𝑅 = 1, 𝐴, 𝐗, 𝑍] and thus ?̌? is not a 
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consistent estimator for 𝜂0. If the missing data probability Pr(𝑅 = 1|𝑌, 𝐴, 𝐗, 𝑍) depends 
on the observed data through (𝐴, 𝐗) only, then it can be easily shown that the complete-
case approach is valid when models (i) is correct and the MAR assumption holds. 
2.2.5.2 The full data approach 
 Full data is the ideal case without missing data (all Z observed) ?̂?𝐹𝐷. Full likelihood 
approach should give out the best estimation results compared with MR and complete cases. 
 There exist other alternative estimators that are consistent for 𝜓 under other 
conditions. For instance, we may use regression to handle confounding bias and then 
weighting to handle missing data. Or we may use DR to handle confounding and then 
weighting to handle missing data.  They are not discussed further in this chapter for space 
constraints.   
 
2.3 Simulation  
 We conducted a simulation study to evaluate the performance of the MR 
estimator ?̂?𝑀𝑅 in the presence of varying degree of selection and confounding bias, and 
compared with the alternative estimators ?̂?𝐶𝐶 and ?̂?𝐹𝐷 in bias, standard error, and 
coverage probability of the 95% CI. 
 We considered the data generating mechanisms as following: 
 We first generated 𝐗 = (𝑋1,⋯ , 𝑋5)  
 𝑋1 follows a mixed uniform distribution 0.35U[40,50] + 0.32U[50,60] +
0.2U[60,70] + 0.07U[70,80] + 0.06U[80,90], and then is rounded to integer for the 
practical meaning of age. 
 𝑋2 follows Bernoulli distribution with a probability 0.5. 
 16 
 𝑋3 follows the multinomial distribution depending  on 𝑋1. (See Table 1) 
 
 𝑋4 follows the standard normal distribution. 
Table 1 Marginal distribution of 𝑋3 
𝑋1 Pr ( 𝑋3= 0) Pr ( 𝑋3= 1) Pr ( 𝑋3= 2) 
≤ 44 0.390 0.297 0.313 
[45, 64] 0.266 0.350 0.384 
[65, 74] 0.261 0.391 0.348 
≥ 75 0.362 0.397 0.241 
 
 Let 𝛽𝑋 = (log1.5 , log 1.5 , log 1.5 , log 1.5)
𝑇 be the coefficient of 𝐗. 
 We then generated the binary confounder 𝑍 based on a conditional mean function 
Pr(𝑍|𝐗) =
1
1+exp(−𝛽0,𝑧−𝛽𝑥𝐗)
, or the continuous confounder 𝑍 based on 𝐸(𝑍|𝐗) =
1
1+exp(−𝛽0,𝑧−𝛽𝑥𝐗)
. 
 We then generated the binary exposure 𝐴 based on the PS function (𝐗, 𝑍) =
1
1+exp(−𝛽0,𝑎−log1.5×𝑍−𝛽𝑥𝐗)
 . 
 We then generated the binary outcome 𝑌 based on a conditional mean function 
𝑏(𝐴, 𝐗, 𝑍) =
1
1+exp(−𝛽0,𝑦−log1.5×𝑍−𝛽𝑥𝐗−log(2)×𝐴)
 
 Finally we generated the missing indicator 𝑅 based on a conditional mean 
function 𝜋(𝑌, 𝐴, 𝐗) =
1
1+exp(−𝛽0,𝑟−𝛽𝑥𝐗−log(1.5)𝐴−log (1.8)𝑌)
 and set the value of 𝑍 to 
missing if  𝑅 = 0.  
 The coefficients (𝛽0,𝑧, 𝛽0,𝑎, 𝛽0,𝑦, 𝛽0,𝑟) were determined such that the marginal 
means of 𝑌, 𝐴, 𝑅, 𝑍 were fixed around 0.1, 0.5, 0.6, and 0.4 (baseline) respectively. Table 
2 presents the marginal mean of other settings.  
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Table 2 Settings for marginal means of 𝑍; 𝐴; 𝑌; 𝑅 
Setting Z A Y R 
1(Baseline) 0.4 0.5 0.1 0.6 
2,3 0.2/0.8 0.5 0.1 0.6 
4,5 0.4 0.2/0.8 0.1 0.6 
6,7 0.4 0.5 0.05/0.1
5 
0.6 
8 0.4 0.5 0.1 0.3 
 In each setting, we conducted 1000 Monte Carlo (MC) trials. We obtained both 
the estimated asymptotic variance and the MC variance of ?̂?𝑀𝑅. We construct the 95% 
Wald CI using the estimated asymptotic variance. To calculate bias we needed to know 
the true value 𝜓0 of 𝜓, we obtained 𝜓0 (with negligible error) by taking the empirical 
average of [𝑏(𝐴 = 1, 𝐗, 𝑍) − 𝑏(𝐴 = 0, 𝐗, 𝑍)] from a million observations available in the 
1000 MC trials. In fitting the data, when we wish to construct a mis-specified working 
model for a particular one of the above 4 functions we simply (incorrectly) set 𝛽𝑥 to 
(0, log 1.5 , log 1.5 , log 1.5)𝑇 in the working model. 
 We present the results for the four considered estimators, ?̂?𝐶𝐶, ?̂?𝑅𝐸𝐺 and ?̂?𝑀𝑅 
across all simulation settings and within each setting, under the following 6 different 
scenarios: 
Scenario 1: working models (i)-(iii) are correct, working model (iv) is “correct” (in 
the sense explained below) 
Scenario 2: working models (i)-(iv) are incorrect 
Scenario 3: working models (i) and (iii) are correct, working models (ii) and (iv) are 
incorrect 
Scenario 4: working models (ii) and (iii) are correct, working models (i) and (iv) are 
incorrect 
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Scenario 5: working model (i) is correct, working model (iv) is correct, working 
models (ii) and (iii) are incorrect 
Scenario 6: working model (ii) is correct, working model (iv) is correct, working 
models (i) and (iii) are incorrect 
 The complete-case estimator ?̂?𝐶𝐶 varies only with the working model (i) for 
𝐸[𝑌|𝐴, 𝐗, 𝑍]. It is not guaranteed to be consistent for 𝜓0 even when model (i) is correct 
because 𝐸[𝑌|𝐴, 𝐗, 𝑍] differs from 𝐸[𝑌|𝑅 = 1, 𝐴, 𝐗, 𝑍] in the considered settings. The MR 
estimator ?̂?𝑀𝑅 varies across all 6 scenarios. It should be consistent in scenarios 1, 3, and 
4. It might be slightly biased in scenarios 5 and 6 with only a correct model (iv). 
 From simulation, we get Table 3 and Table 4 for missing binary/continuous 
covariate Z under the baseline setting. 
Table 3 Baseline results for missing binary covariate Z 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.810 0.564     
FD 0.959 0.901     
MR 0.946 0.888 0.942 0.947 0.944 0.946 
Bias 
CC 0.022 0.035     
FD -0.001 0.013     
MR -0.001 0.013 -0.002 -0.001 -0.002 -0.001 
MC SE 
CC 0.023 0.020     
FD 0.021 0.020     
MR 0.022 0.021 0.022 0.022 0.022 0.022 
Average 
Analytic 
SE 
CC 0.024 0.021     
FD 0.021 0.021     
MR 0.022 0.021 0.022 0.022 0.022 0.022 
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Table 4 Baseline results for missing continuous covariate Z 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.859 0.758     
FD 0.937 0.875     
MR 0.929 0.885 0.933 0.935 0.934 0.930 
Bias 
CC 0.017 0.030     
FD 0.001 0.015     
MR 0.001 0.015 0.001 0.001 0.002 0.001 
MC SE 
CC 0.028 0.027     
FD 0.022 0.021     
MR 0.023 0.022 0.022 0.023 0.022 0.023 
Average 
Analytic 
SE 
CC 0.027 0.026     
FD 0.021 0.020     
MR 0.022 0.021 0.022 0.022 0.022 0.022 
  
 For both baseline settings, we could find the MR estimate ?̂?𝑀𝑅 gives us 
acceptable bias and its coverage probabilities based on the empirical asymptotic variance 
are close to nominal level in most of the scenarios except for all models incorrect. The 
results also shows the MC SE is close to the average asymptotic variance estimate of 
?̂?𝑀𝑅, which verifies the correctness  of estimation of asymptotic variance of ?̂?𝑀𝑅. 
Compared with ?̂?𝐶𝐶 under scenario 1, the performance of ?̂?𝑀𝑅 is much better (higher 
coverage probability, smaller bias and smaller estimated asymptotic variance); while 
compared with ?̂?𝐹𝐷, ?̂?𝑀𝑅’s bias and coverage probability is very close to ?̂?𝐹𝐷’s under 
scenario 1 and 2. 
 For the setting 2~8, we summarize the results in the following tables, 5 through 
18.  
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Table 5 Results for missing binary covariate Z in setting 2 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.868 0.680     
FD 0.949 0.899     
MR 0.939 0.891 0.942 0.943 0.940 0.940 
Bias 
CC 0.017 0.031     
FD -0.001 0.013     
MR 0.000 0.013 -0.002 -0.001 -0.002 -0.000 
MC SE 
CC 0.025 0.022     
FD 0.021 0.020     
MR 0.022 0.021 0.022 0.023 0.022 0.023 
Average 
Analytic 
SE 
CC 0.024 0.022     
FD 0.021 0.020     
MR 0.021 0.021 0.021 0.022 0.021 0.022 
 
Table 6 Results for missing binary covariate Z in setting 3 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.658 0.427     
FD 0.968 0.894     
MR 0.950 0.889 0.952 0.951 0.951 0.952 
Bias 
CC 0.027 0.039     
FD 0.000 0.014     
MR 0.000 0.014 0.000 0.000 0.000 0.000 
MC SE 
CC 0.025 0.020     
FD 0.021 0.020     
MR 0.021 0.021 0.021 0.021 0.021 0.021 
Average 
Analytic 
SE 
CC 0.024 0.019     
FD 0.025 0.023     
MR 0.021 0.020 0.021 0.021 0.021 0.021 
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Table 7 Results for missing binary covariate Z in setting 4 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.818 0.600     
FD 0.961 0.937     
MR 0.940 0.938 0.930 0.942 0.928 0.944 
Bias 
CC 0.018 0.029     
FD 0.001 0.011     
MR -0.001 0.011 0.000 0.000 0.000 0.000 
MC SE 
CC 0.019 0.018     
FD 0.018 0.019     
MR 0.035 0.022 0.022 0.028 0.021 0.021 
Average 
Analytic 
SE 
CC 0.019 0.018     
FD 0.019 0.020     
MR 0.021 0.021 0.021 0.021 0.020 0.020 
 
Table 8 Results for missing binary covariate Z in setting 5 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.825 0.678     
FD 0.940 0.886     
MR 0.920 0.879 0.919 0.921 0.917 0.922 
Bias 
CC 0.028 0.043     
FD 0.002 0.019     
MR 0.003 0.020 0.002 0.003 0.001 0.003 
MC SE 
CC 0.041 0.036     
FD 0.032 0.030     
MR 0.041 0.037 0.039 0.041 0.039 0.042 
Average 
Analytic 
SE 
CC 0.040 0.034     
FD 0.033 0.031     
MR 0.040 0.036 0.038 0.040 0.038 0.041 
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Table 9 Results for missing binary covariate Z in setting 6 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.820 0.650     
FD 0.951 0.916     
MR 0.936 0.905 0.943 0.931 0.940 0.933 
Bias 
CC 0.012 0.020     
FD -0.001 0.007     
MR -0.001 0.007 -0.001 -0.001 -0.001 -0.001 
MC SE 
CC 0.018 0.015     
FD 0.016 0.016     
MR 0.017 0.016 0.017 0.017 0.017 0.017 
Average 
Analytic 
SE 
CC 0.018 0.015     
FD 0.017 0.016     
MR 0.017 0.016 0.017 0.017 0.017 0.017 
 
Table 10 Results for missing binary covariate Z in setting 7 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.813 0.542     
FD 0.954 0.875     
MR 0.946 0.880 0.943 0.931 0.940 0.933 
Bias 
CC 0.027 0.046     
FD 0.000 0.018     
MR 0.000 0.018 -0.001 0.000 -0.001 0.000 
MC SE 
CC 0.028 0.025     
FD 0.024 0.024     
MR 0.025 0.025 0.017 0.017 0.017 0.017 
Average 
Analytic 
SE 
CC 0.028 0.025     
FD 0.024 0.024     
MR 0.025 0.024 0.017 0.017 0.017 0.017 
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Table 11 Results for missing binary covariate Z in setting 8 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.789 0.667     
FD 0.965 0.905     
MR 0.961 0.900 0.946 0.958 0.943 0.957 
Bias 
CC 0.025 0.038     
FD 0.000 0.014     
MR 0.000 0.014 -0.001 0.000 -0.001 0.000 
MC SE 
CC 0.035 0.030     
FD 0.021 0.020     
MR 0.023 0.022 0.023 0.023 0.023 0.023 
Average 
Analytic 
SE 
CC 0.035 0.030     
FD 0.023 0.022     
MR 0.023 0.022 0.023 0.023 0.023 0.023 
 
Table 12 Results for missing continuous covariate Z in setting 2 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.894 0.787     
FD 0.944 0.901     
MR 0.946 0.910 0.942 0.949 0.943 0.947 
Bias 
CC 0.014 0.027     
FD -0.001 0.013     
MR -0.001 0.013 -0.001 -0.001 -0.001 -0.001 
MC SE 
CC 0.028 0.026     
FD 0.021 0.020     
MR 0.022 0.021 0.022 0.022 0.022 0.022 
Average 
Analytic 
SE 
CC 0.027 0.026     
FD 0.021 0.020     
MR 0.022 0.021 0.021 0.022 0.021 0.022 
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Table 13 Results for missing continuous covariate Z in setting 3 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.893 0.788     
FD 0.950 0.884     
MR 0.946 0.876 0.943 0.949 0.942 0.948 
Bias 
CC 0.015 0.028     
FD 0.000 0.014     
MR 0.000 0.014 0.000 0.000 0.000 0.000 
MC SE 
CC 0.027 0.026     
FD 0.021 0.021     
MR 0.022 0.021 0.022 0.022 0.022 0.022 
Average 
Analytic 
SE 
CC 0.027 0.026     
FD 0.021 0.020     
MR 0.021 0.021 0.021 0.022 0.021 0.022 
 
Table 14 Results for missing continuous covariate Z in setting 4 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.920 0.845     
FD 0.944 0.928     
MR 0.949 0.938 0.945 0.947 0.945 0.950 
Bias 
CC 0.012 0.023     
FD 0.000 0.010     
MR 0.000 0.010 0.000 0.000 0.000 0.000 
MC SE 
CC 0.023 0.023     
FD 0.019 0.020     
MR 0.021 0.022 0.021 0.021 0.021 0.021 
Average 
Analytic 
SE 
CC 0.022 0.023     
FD 0.019 0.020     
MR 0.020 0.021 0.020 0.020 0.020 0.020 
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Table 15 Results for missing continuous covariate Z in setting 5 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.866 0.802     
FD 0.921 0.881     
MR 0.925 0.898 0.930 0.922 0.930 0.924 
Bias 
CC 0.018 0.034     
FD 0.000 0.017     
MR -0.001 0.017 -0.001 -0.001 0.000 0.000 
MC SE 
CC 0.048 0.044     
FD 0.035 0.032     
MR 0.041 0.037 0.039 0.042 0.038 0.042 
Average 
Analytic 
SE 
CC 0.045 0.042     
FD 0.033 0.031     
MR 0.040 0.036 0.038 0.040 0.037 0.040 
 
Table 16 Results for missing continuous covariate Z in setting 6 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.891 0.822     
FD 0.951 0.912     
MR 0.946 0.911 0.948 0.948 0.948 0.948 
Bias 
CC 0.008 0.016     
FD -0.001 0.007     
MR -0.001 0.007 -0.001 -0.001 0.000 0.000 
MC SE 
CC 0.021 0.019     
FD 0.016 0.015     
MR 0.017 0.016 0.017 0.017 0.017 0.017 
Average 
Analytic 
SE 
CC 0.021 0.019     
FD 0.016 0.015     
MR 0.017 0.016 0.017 0.017 0.017 0.017 
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Table 17 Results for missing continuous covariate Z in setting 7 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.883 0.748     
FD 0.957 0.873     
MR 0.957 0.883 0.954 0.954 0.952 0.955 
Bias 
CC 0.020 0.038     
FD 0.001 0.019     
MR 0.001 0.019 0.001 0.001 0.001 0.001 
MC SE 
CC 0.032 0.031     
FD 0.024 0.024     
MR 0.025 0.024 0.024 0.025 0.024 0.025 
Average 
Analytic 
SE 
CC 0.031 0.030     
FD 0.024 0.024     
MR 0.025 0.024 0.025 0.025 0.024 0.025 
 
Table 18 Results for missing continuous covariate Z in setting 8 
Estimate 
Scenario 
1 2 3 4 5 6 
Coverage 
Pr 
CC 0.879 0.817     
FD 0.944 0.872     
MR 0.939 0.894 0.936 0.939 0.942 0.941 
Bias 
CC 0.018 0.031     
FD 0.000 0.014     
MR 0.000 0.014 0.000 0.000 0.001 0.001 
MC SE 
CC 0.041 0.038     
FD 0.022 0.021     
MR 0.024 0.023 0.024 0.024 0.023 0.024 
Average 
Analytic 
SE 
CC 0.039 0.037     
FD 0.021 0.020     
MR 0.023 0.022 0.023 0.024 0.022 0.023 
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 For both missing binary and continuous covariate 𝑍, we could find the MR 
estimate  has lower coverage probability when 𝑃𝑟 (𝐴 =  1) =  0.8 (setting 5) compared 
with other settings. Besides, ?̂?𝑀𝑅 has a lower coverage probability when 𝐴 model was 
wrong. The range of marginal means of our simulation settings covered most practical 
settings where the multiply robust approach would have good performance. 
 
2.4 Discussion 
 Based on the MR estimator ?̂?𝑀𝑅 for the average causal effect of a treatment in the 
presence of missing binary confounder data, we extent the method to the observational 
data with a missing continuous confounder. We demonstrated that ?̂?𝑀𝑅was robust to 
model misspecification that it was consistent for the average treatment effect if one of the 
four conditions held: model (i) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] and model (iii) for Pr(𝑅 = 1|𝑌, 𝐴, 𝐗) 
were correct, model (ii) for Pr(𝐴 = 1|𝐗, 𝑍) and model (iii) were correct, model (i) and 
model (iv) for Pr (𝑍 = 1|𝑅 = 1, 𝑌, 𝐴, 𝐗) were correct, and models (ii) and (iv) were 
correct. We also developed the asymptotic variance for ?̂?𝑀𝑅 when either missing binary 
or continuous variable exists. A simulation study was carried out to evaluated the 
estimate’s performance in many aspects. 
 In this chapter, the MR estimator provides a promising unified approach to the 
estimation of causal effects in the presence of one missing binary/continuous confounder 
data in observational studies. In principal, the methodology can be extended to handle 
one or several categorical or continuous confounders 𝐙. When all components of 𝐙 are 
discrete and have a small number of covariate levels, the conditional mean of any 
function ℎ(𝑌, 𝐴, 𝐗, 𝑍) given (𝑅 = 1, 𝑌, 𝐴, 𝐗) can be easily calculated as a sum over all 
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possible covariate levels of 𝐙. When 𝐙 has at least one continuous component or a large 
number of possible covariate levels, the conditional mean function can be estimated by 
fitting a parametric working model for 𝐸[ℎ(𝑌, 𝐴, 𝐗, 𝑍)|𝑅 = 1, 𝑌, 𝐴, 𝐗] among the 
complete cases. 
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CHAPTER 3. AN INVERSE PROBABILITY WEIGHTING APPROACH FOR 
HISTORICAL CONTROL AUGMENTED RANDOMIZED CLINICAL TRIALS 
3.1 Background 
 The randomized control trial (RCT) is often considered as the gold standard for 
evaluating the effectiveness or safety of various types of medical interventions. Patients 
in RCT are randomly allocated to different treatments under study so that patients across 
treatments are reasonably comparable in both known and unknown prognostic factors. 
After randomization, the two (or more) groups of patients are followed in exactly the 
same way, leaving the treatment that the patients receive as the main difference.  
 An alternative of RCT is the single arm trial where all patients in the current study 
will receive the new treatment, which the investigators believe to be superior. 
Nevertheless, due to the lack of randomization, the single arm trial may lead to biased 
estimates of the treatment effect when the comparability between the historical and 
current study is not ensured. Historical and current trial may differ in a number of ways 
including the change in supporting care, the distribution of patient characteristics, the 
method of the effect evaluation and the inter-institution variability. Thus the single arm 
trial is usually considered appropriate mostly in situations where the well-defined 
historical data are available or accrual is a problem in rare disease settings [17, 18].  
 A comprise between the single-arm trial and regular RCT for the new treatment is 
a RCT with the current control group augmented by relevant historical controls[19]. To 
avoid a systematic bias in such type of clinical trial design, the acceptability of the 
historical data should be carefully evaluated, in a prospective rather than a post hoc 
manner. Generally, the historical data should come from a randomized trial with the same 
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(or similar) patient eligibility and the same effect evaluation method. The historical trial 
should usually be performed in the same organization with largely the same investigators, 
and no apparent dissimilarity in other aspects of study design such as accrual rate [19]. 
Even under most stringent scrutiny, the prospectively selected historical controls are 
generally not considered as reliable as the randomized control. It is expected that some 
degree of bias might exist in historical data with both the magnitude and direction not 
predictable before the current trial.  
 Various approaches have been proposed for combining current and historical 
control to achieve the statistical efficiency while protecting against the potential biases 
[19-24]. Such methods include the test-then-pool[19], power priors[20] and hierarchical 
Bayesian models [21, 22](see [25] for an excellent review). For the situations that 
inconsistency of the two sources of data can be explained by the measured covariates, it 
is recognized that we could calibrate the current and historical controls via the covariate 
adjustment using either regression or propensity score methodology in Bayesian 
approach. [11, 26, 27] We could also consider the combining problem as a confounding 
problem in observational study. However, using inverse probability weighting (IPW) 
method for confounding problem hasn’t been explored yet. Compared with Bayesian 
models, IPW method avoids the selection of prior and still help to improve the efficiency. 
 Our research is motivated by the need of an efficient trial design for finding novel 
treatments for amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative 
disease currently with no cure, affecting about 30,000 Americans. Riluzole is the only 
FDA-approved treatment that has small but significant beneficial effect in prolonging life 
span and slowing declines in some motor function of ALS patients [28-30]. It is generally 
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reported that the median survival time of ALS patients from symptom onset is 2 to 5 
years[31], but the survival time of individual ALS patients varies widely. There are many 
known prognostic factors that are associated with ALS patient survival times. 
Investigators found it important to include these known prognostic factors in the primary 
analysis of the clinical trials evaluating the survival effectiveness of Riluzole [30]. 
Similarly, it may be even more crucial to include known prognostic factors into any type 
of models for combining historical data in ALS trials. With a recent resurgence in the 
number of ALS clinical trials, more relevant historical information may be available for 
augmenting future ALS trials [32]. Specifically, a randomized, double-blind, placebo-
controlled phase 3 trial on ALS (EMPOWER) was recently completed that contain 468 
patients on the placebo group [33]. We are interested in developing an appropriate 
frequentist method to incorporate EMPOWER control data to potentially improve the 
efficiency of future trial design on ALS.    
 In the following sections, we first introduce our notation. Then we present the 
new IPW estimates for continuous and time-to-event response. We carry out a simulation 
study for the time-to-event response and compare the results from IPW estimates with 
other estimates (from not combining historical controls).  Finally, we conclude our paper 
with a brief discussion. 
 
3.2 Methods 
 In this section, we begin with the most straightforward outcome, continuous 
response, then we extend the similar idea to the time-to-event response, which is 
consistent with our motivation example. 
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3.2.1 IPW estimates for continuous 
3.2.1.1 Notation 
 We collect data from one RCT and the qualified historical controls. There’re two 
arms (with/without intervention) for three groups: treatment group in trial receiving 
intervention (group T), control group in trial not receiving intervention (group C) and 
historical control group not in trial not receiving intervention (group H). In Table 19, 𝐼1 
and 𝐼2 are the indicators for three groups. We define the population B for the population 
not receiving treatment, from which we select group C and group H patients into the 
study.  
Table 19 Indicators for three arms 
           Group 
Indicator 
T C H 
𝐼1 1 0 0 
𝐼2 0 1 0 
  
 Let 𝑖 = 1,… , 𝑛𝑇 denote the subjects in group T; 𝑗 = 1,… , 𝑛𝐶 denote the subjects 
in group C; 𝑘 = 1,… , 𝑛𝐻 denote the subjects in group H; 𝑙 = 1,… , 𝑛1 = 𝑛𝐶 + 𝑛𝐻 denote 
all the subjects in population B; 𝑚 = 1,… , 𝑛2 = 𝑛𝑇 + 𝑛𝐶  denote all the subjects in RCT; 
𝑞 = 1,… ,𝑁 denote all the subjects in the study. 
 For each subject, 𝑌 denotes the observed response; 𝐗 denotes the covariates; 𝑒 =
Pr(𝐼2 = 1|𝐗) denotes the propensity score for population B. For subject 𝑙, 
𝐼2𝑙~𝐵𝑒𝑟𝑛𝑜𝑙𝑙𝑖 (𝑒(𝐗𝑙, 𝛽) = Pr(𝐼2𝑙 = 1|𝐗𝑙,𝛽) =
exp(𝑋𝑙
′𝛽)
1+exp(𝐗𝑙
′𝛽)
). The estimated parameter 𝛽 
and propensity score 𝑒𝑙 = 𝑒(𝑋𝑙, 𝛽) could be obtained through logistic regression from 
population B. We define random variables (R.V.): 
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 𝑆 =
𝐼2
𝑒
𝑌; 𝑊 =
(1−𝐼2)
1−𝑒
𝑌; 𝐾 =
(1−𝐼2)
𝑒
𝑌; 𝐿 =
𝐼2
1−𝑒
𝑌; 𝑈 = 𝑒𝑌. 
 𝑆𝑙
∗ = 𝑆𝑙(𝛽
∗) =
𝐼2𝑙
𝑒𝑙(𝛽∗)
𝑌𝑙, where 𝛽
∗is the truth of 𝛽. 
 For the populations/groups, we have 
 𝐸𝐵
𝑆 denotes for the true mean of R.V. 𝑆 from population B. 𝑃𝑛1(𝑆𝑙) =
1
𝑛1
∑ 𝑆𝑙
𝑛1
𝑙=1  
denotes for the sample mean of R.V. 𝑆 using samples from population B. 
 𝑉𝑎𝑟𝐵
𝑌 = 𝐸𝐵
𝑌2 − (𝐸𝐵
𝑌)2 denotes for the true variance of R.V. 𝑌 from population B. 
𝑉𝐵
𝑌 = 𝑃𝑛1(𝑌𝑙
2) − [𝑃𝑛1(𝑌𝑙)]
2
 denotes the sample variance of R.V. 𝑌 using samples 
from population B.  
 𝐶𝑜𝑣𝐶(𝑌, 𝑆) = 𝐸𝐶
𝑌𝑆 − 𝐸𝐶
𝑌𝐸𝐶
𝑆 denotes for the true covariance of R.V. 𝑌 and 𝑆 from 
group C. Sample covariance 𝑄𝐶(𝑌, 𝑆) = 𝑃𝑛𝑐(𝑌𝑗𝑆𝑗) − 𝑃𝑛𝑐(𝑌𝑗)𝑃𝑛𝑐(𝑆𝑗) denotes for 
the covariance of R.V. 𝑌 and 𝑆 using samples from group C. 
3.2.1.2 IPW Estimate for continuous response 
 Let 𝜃 denote for the treatment effects of the intervention, which is our parameter 
of interest 
𝜃 = 𝐸(𝑌1) − 𝐸(𝑌0) 
𝑌1 and 𝑌0 denotes for the response from the subject receiving/not receiving intervention.  
 First, we could construct the estimate for 𝜃 only based on the trial data using the 
sample average: 
 𝜃1 = 𝑢
1 − 𝑢0 (7)  
where 𝑢1 = 𝑌𝑇̅̅ ̅ =
1
𝑛𝑇
∑ 𝑌𝑖𝑖∈𝑇 , 𝑢
0 = 𝑌?̅? =
1
𝑛𝐶
∑ 𝑌𝑗𝑗∈𝐶 . 𝑉𝑎𝑟(𝜃1) =
1
𝑛𝑇
𝑉𝑎𝑟𝑇
𝑌 +
1
𝑛𝐶
𝑉𝑎𝑟𝐶
𝑌.  
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 Next, we construct four estimates from combining current controls and historical 
controls. 
1. Historical controls are combined into current controls and viewed as part of RCT on 
the arm without intervention. 𝜃2 is the estimates of the average treatment effects over 
the treated (ATT). 𝐸(𝑌𝐵
1) means the expected response from population B when 
receive the treatment. Let 𝑔 = Pr(𝐼1 = 1|𝑋) =
Pr(𝐼1=1,𝑋)
Pr(𝑋)
=
𝑒
1+𝑒
. 𝐸(𝑌𝐵
1) =
∑
(1−𝐼1𝑞)𝑔𝑎
1−𝑔𝑞
𝑌𝑞
𝑁
𝑞=1 . 
𝜃2 =
1
Pr(𝐼1 = 1)
[𝐸(𝑌𝑇
1) − 𝐸(𝑌𝐵
1)] =
1
𝑛𝑇
𝑁
×
1
𝑁
∑[𝐼1𝑞 −
(1 − 𝐼1𝑞)𝑔𝑞
1 − 𝑔𝑞
] 𝑌𝑞
𝑁
𝑞=1
 
=
1
𝑛𝑇
[∑𝑌𝑖
𝑛𝑇
𝑖=1
−∑
𝑔𝑙
1 − 𝑔𝑙
𝑌𝑙
𝑛1
𝑙=1
] =
1
𝑛𝑇
[∑𝑌𝑖
𝑛𝑇
𝑖=1
−∑𝑒𝑙𝑌𝑙
𝑛1
𝑙=1
] = 𝑢1 −
𝑛1
𝑛𝑇
𝑃𝑛1(𝑈𝑙) 
(8)  
Thus we have 
𝑉𝑎𝑟(𝜃2) =
1
𝑛𝑇
𝑉𝑇
𝑌 +
𝑛1
2
𝑛𝑇
2 ⋅
1
𝑛1
𝑉𝑎𝑟(𝑈) =
1
𝑛𝑇
𝑉𝑇
𝑌 +
𝑛1
𝑛𝑇
2 𝑉𝐵
𝑈 
(9)  
2. We could construct the unbiased estimates  
𝜃𝑟+2 = 𝜃1 + 𝑎 Δ𝑟 , 𝑟 = 1,… ,3. (10)  
Thus 𝑉𝑎𝑟(𝜃𝑟+2) = 𝑉𝑎𝑟(𝜃1 + 𝑎 Δ𝑟). Here  Δ𝑟 estimates the effect of getting involved in 
RCT in population B. To get  Δ𝑟, we have three kinds of estimates of response from 
population B 
𝑑1 = 𝑃𝑛1(𝑌𝑙), 𝑑2 = 𝑃𝑛1(𝑆𝑙), 𝑑3 = 𝑃𝑛1(𝑊𝑙) (11)  
So we could construction 
a. Δ1 = 𝑑2 − 𝑑3 = 𝑃𝑛1(𝑆𝑙 −𝑊𝑙). 
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b. Δ2 = 𝑑1 − 𝑑2 = 𝑃𝑛1(𝑌𝑙 − 𝑆𝑙) =
1
𝑛1
(∑ 𝑌𝑘𝑘∈𝐻 − ∑
1−𝑒𝑗
𝑒𝑗
𝑌𝑗𝑗∈𝐶 ). 
c. Δ3 = 𝑑1 − 𝑑3 = 𝑃𝑛1(𝑌𝑙 −𝑊𝑙) =
1
𝑛1
(∑ 𝑌𝑗𝑗∈𝐶 −∑
𝑒𝑘
1−𝑒𝑘
𝑌𝑘𝑘∈𝐻 ). 
To find the most efficient 𝜃𝑟+2, we minimize 𝑉𝑎𝑟(𝜃𝑟+2) and find the parameter 𝑎
∗ =
−
𝐶𝑜𝑣(?̂?1, Δ𝑟)
𝑉𝑎𝑟( Δ𝑟)
. We simply use 𝜃𝑟+2 for 𝜃𝑟+2|𝑎∗ and we have 
𝑉𝑎𝑟(𝜃𝑟+2) = 𝑉𝑎𝑟(𝜃1) −
𝐶𝑜𝑣(𝜃1, Δ𝑟)
2
𝑉𝑎𝑟(Δ𝑟)
= (1 − 𝜌2)𝑉𝑎𝑟(𝜃1) ≤ 𝑉𝑎𝑟(𝜃1) 
(12)  
Here 𝜌 =
𝑐𝑜𝑣(?̂?1,Δ𝑟)
√𝑉𝑎𝑟(?̂?1)𝑉𝑎𝑟(Δ𝑟)
. The large 𝜌2 is, the more efficient 𝜃𝑟+2 is. 
3.2.2 IPW estimate for time-to-event response 
3.2.2.1 Notation 
 𝐼1 and 𝐼2 are the indicators for group T and group C.   
 𝑛𝐶 , 𝑛1 and 𝑛2 dare the number of subjects in group C, group C + group H and 
RCT respectively; 
 𝑌𝑖 = (𝛿𝑖, 𝑇𝑖) denotes the response for subject 𝑖, where 𝛿𝑖 is the censoring indicator 
(𝛿𝑖 = 0 means subject 𝑖 is censored) and 𝑇𝑖 is the survival time. 
 𝐗𝑖 is the covariates of subject 𝑖 and 𝜋𝑖 = Pr(𝐼2𝑖 = 1|𝐗𝑖) is the propensity score of 
being in group C. 
3.2.2.2 Efficient score function 
 In a standard RCT with two arms, let 𝐼 be the indicator for the treatment arm and 
𝑛 be the total number of subjects in the study. Based on cox model assuming proportional 
hazard assumption holds, we have the hazard rate function 
𝜆(𝑡) = 𝜆0(𝑡) exp(𝜃𝐼𝑖) 
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And the partial likelihood could be written as 
𝐿(𝜃) =∏(
exp(𝜃𝐼𝑖)
𝛴𝑗∈𝑅𝑖(exp(𝜃𝐼𝑗))
)
𝛿𝑖𝑛
𝑖=1
 
where 𝑅𝑖 = {𝑗: 𝑇𝑗 ≥ 𝑇𝑖}. The log partial likelihood: 
𝑙(𝜃) = log 𝐿(𝜃) =∑𝛿𝑖{𝜃𝐼𝑖 − log[𝛴𝑗∈𝑅𝑖(exp(𝜃𝐼𝑗))]}
𝑛
𝑖=1
 
Therefore we have the score function:  
𝜕𝑙
𝜕𝜃
=∑𝛿𝑖 {𝐼𝑖 −
𝛴𝑗∈𝑅𝑖(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑖(exp(𝜃𝐼𝑗))
}
𝑛
𝑖=1
= 0 
We use MLE to get 𝜃. Let 𝑙𝜃(𝑌𝑖) = 𝛿𝑖 {𝐼𝑖 −
𝛴𝑗∈𝑅𝑖
(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑖
(exp(𝜃𝐼𝑗))
}. Then 
𝜕𝑙
𝜕𝜃
= ∑ 𝑙𝜃(𝑌𝑖). 
 According to Eq(31) from [34], the efficient score function 𝑙𝜃,Λ
∗  for subject 𝑖 is  
𝑙𝜃,Λ
∗ (𝑌𝑖) = 𝛿𝑖 {𝐼𝑖 −
𝛴𝑗∈𝑅𝑖
(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑖
(exp(𝜃𝐼𝑗))
} − exp(𝜃𝐼𝑖) ∫ {𝐼𝑖 −
𝛴𝑗∈𝑅𝑘(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗))
}
𝑡𝑖
0
𝑑Λ(𝑡𝑘)After 
plugging the estimated baseline functiion 𝑑Λ̂(𝑡𝑘) = ℎ̂(𝑡𝑘) = 𝛿𝑘
1
𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗))
, we have  
𝑙𝜃,Λ̂
∗ (𝑌𝑖) = 𝛿𝑖 {𝐼𝑖 −
𝛴𝑗∈𝑅𝑖(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑖(exp(𝜃𝐼𝑗))
}
− exp(𝜃𝐼𝑖) ∑ {[𝐼𝑖 −
𝛴𝑗∈𝑅𝑘(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗))
] × [𝛿𝑘
1
𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗))
]}
𝑡𝑘≤𝑡𝑖
 
= 𝛿𝑖 {𝐼𝑖 −
𝛴𝑗∈𝑅𝑖(𝐼𝑗 exp(𝜃𝐼𝑗))
𝛴𝑗∈𝑅𝑖(exp(𝜃𝐼𝑗))
}
− exp(𝜃𝐼𝑖) ∑ {𝛿𝑘 [
𝐼𝑖
𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗))
−
𝛴𝑗∈𝑅𝑘(𝐼1𝑗 exp(𝜃𝐼𝑗))
(𝛴𝑗∈𝑅𝑘(exp(𝜃𝐼𝑗)))
2]}
𝑡𝑘≤𝑡𝑖
 
This is consistent with Eq(2) from [35].  
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 For inverse probability weighting (IPW) Cox model, 𝑑Λ̂(𝑡𝑘) = ℎ̂(𝑡𝑘) =
𝛿𝑘
𝜋𝑘×𝛴𝑗∈𝑅𝑘(exp
(𝜃𝐼𝑗)
𝜋𝑗
)
 and the efficient score function is: 
𝑙𝜃,Λ̂
∗ (𝑌𝑖) = 𝛿𝑖
{
 
 
 
 
𝐼𝑖 −
𝛴𝑗∈𝑅𝑖 (
𝐼𝑗 exp(𝜃𝐼𝑗)
𝜋𝑗
)
𝛴𝑗∈𝑅𝑖 (
exp(𝜃𝐼𝑗)
𝜋𝑗
)
}
 
 
 
 
− exp(𝜃𝐼𝑖) ∑
{
 
 
 
 
[
 
 
 
 
𝐼𝑖 −
𝛴𝑗∈𝑅𝑘 (
𝐼𝑗 exp(𝜃𝐼𝑗)
𝜋𝑗
)
𝛴𝑗∈𝑅𝑘 (
exp(𝜃𝐼𝑗)
𝜋𝑗
)
]
 
 
 
 
𝑡𝑘≤𝑡𝑖
×
[
 
 
 
 
𝛿𝑘
1
𝜋𝑘 × 𝛴𝑗∈𝑅𝑘 (
exp(𝜃𝐼𝑗)
𝜋𝑗
)
]
 
 
 
 
}
 
 
 
 
 
= 𝛿𝑖
{
 
 
 
 
𝐼𝑖 −
𝛴𝑗∈𝑅𝑖 (
𝐼𝑗 exp(𝜃𝐼𝑗)
𝜋𝑗
)
𝛴𝑗∈𝑅𝑖 (
exp(𝜃𝐼𝑗)
𝜋𝑗
)
}
 
 
 
 
− exp(𝜃𝐼𝑖) ∑
{
 
 
 
 
𝛿𝑘
𝜋𝑘
[
 
 
 
 
 
𝐼𝑖
𝛴𝑗∈𝑅𝑘 (
exp(𝜃𝐼𝑗)
𝜋𝑗
)
−
𝛴𝑗∈𝑅𝑘 (
𝐼𝑗 exp(𝜃𝐼𝑗)
𝜋𝑗
)
(𝛴𝑗∈𝑅𝑘 (
exp(𝜃𝐼𝑗)
𝜋𝑗
))
2
]
 
 
 
 
 
}
 
 
 
 
𝑡𝑘≤𝑡𝑖
 
Here the baseline function is estimated as 𝑑Λ̂(𝑡𝑘) = ℎ̂(𝑡𝑘) = 𝛿𝑘
1
𝛴𝑗∈𝑅𝑘(
exp(𝜃𝐼𝑗)
𝜋𝑗
)
  according 
to Eq(35) from [34]. 𝜃0 denotes the truth of 𝜃. The information matrix based on the score 
function is  
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𝐼𝜃0 = −
1
𝑛2
×
𝜕𝑙2
𝜕𝜃2
|𝜃0 =
−
1
𝑛2
∑ −𝛿𝑖
𝛴𝑗∈𝑅𝑖[exp
(𝜃0𝐼𝑗)𝐼𝑗
2]𝛴𝑗∈𝑅𝑖
(exp(𝜃0𝐼𝑗))−𝛴𝑗∈𝑅𝑖
[𝐼1𝑗 exp(𝜃0𝐼𝑗)]𝛴𝑗∈𝑅𝑖
[𝐼𝑗 exp(𝜃0𝐼𝑗)]
[𝛴𝑗∈𝑅𝑖
(exp(𝜃0𝐼𝑗))]
2
 
𝑛2
𝑖=1   
=
1
𝑛2
∑𝛿𝑖 [
𝛴𝑗∈𝑅𝑖[exp(𝜃0𝐼𝑗) 𝐼𝑗
2]
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
− (
𝛴𝑗∈𝑅𝑖[𝐼𝑗 exp(𝜃0𝐼𝑗)]
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
)
2
]
𝑛
𝑖=1
 
Therefore we have 
𝑉𝑎𝑟(𝜃) = (𝑛 ∗ 𝐼𝜃0
−1)∑(
𝑙𝜃,Λ̂
∗ (𝑌𝑖)
𝜋𝑖
)
2
(𝑛 ∗ 𝐼𝜃0
−1)
𝑛
𝑖=1
 
 According to Eq(32) from [34], the Information matrix is 
𝐼𝜃0 = 𝑃0 (exp(𝜃0𝐼𝑖)∫ {𝐼𝑖 −
𝛴𝑗∈𝑅𝑘(𝐼𝑗 exp(𝜃0𝐼𝑗))
𝛴𝑗∈𝑅𝑘(exp(𝜃0𝐼𝑗))
}
⊗2𝜏
0
Pr(𝑇 ≥ 𝑡𝑘|𝐼𝑖) 𝑑Λ0(𝑡𝑘)) 
Based on (3.21) from Fleming and Harrington [36], we have 
𝑉(𝜃0, 𝑡𝑖) =
𝛴𝑗∈𝑅𝑖[exp(𝜃0𝐼𝑗) 𝐼𝑗
2]
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
− (
𝛴𝑗∈𝑅𝑖[𝐼𝑗 exp(𝜃0𝐼𝑗)]
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
)
2
 
It’s been proved that (3.23) is equivalent to (3.21) and in our setting 
𝑉(𝜃0, 𝑡𝑖) =
1
𝑛2
⋅
∑ [(𝐼𝑖 −
𝛴𝑗∈𝑅𝑘[𝐼𝑗 exp(𝜃0𝐼𝑗)]
𝛴𝑗∈𝑅𝑘(exp(𝜃0𝐼𝑗))
)
⊗2
𝑌𝑘(𝑡𝑖) exp(𝜃0𝐼𝑖)]
𝑛
𝑘=1
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
 
=
exp(𝜃0𝐼𝑖)∑ [(𝐼𝑖 −
𝛴𝑗∈𝑅𝑘[𝐼𝑗 exp(𝜃0𝐼𝑗)]
𝛴𝑗∈𝑅𝑘(exp(𝜃0𝐼𝑗))
)
⊗2
𝑌𝑘(𝑡𝑖)
𝑛2
]𝑛𝑘=1
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
 
=
exp(𝜃0𝐼𝑖)∑ [(𝐼1𝑖 −
𝛴𝑗∈𝑅𝑘[𝐼𝑗 exp(𝜃0𝐼𝑗)]
𝛴𝑗∈𝑅𝑘(exp(𝜃0𝐼𝑗))
)
⊗2
Pr(𝑇 ≥ 𝑡𝑘|𝐼𝑖)]
𝑛
𝑘=1
𝛴𝑗∈𝑅𝑖(exp(𝜃0𝐼𝑗))
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After plugging the estimated baseline functiion 𝑑Λ̂0(𝑡𝑘) = ℎ̂0(𝑡𝑘) = 𝛿𝑘
1
𝛴𝑗∈𝑅𝑘(
exp(𝜃𝐼𝑗)
𝜋𝑗
)
, 
we could prove that two information matrix formulas are the same. 
3.2.2.3 IPW estimate for time-to-event response 
 Parameter of interest 𝜃 is the log hazard ratio between treated and control. We 
first construct the estimate for 𝜃 only based on the trial data using Cox model. 𝜃0 denote 
the truth of 𝜃. Using Taylor expansion, we have 
𝐼𝜃0√𝑛2(𝜃1 − 𝜃0) =
1
√𝑛2
∑𝑙𝜃0,Λ̂
∗ (𝑌𝑖)
𝑛2
𝑖=1
+ 𝑂𝑝(1) 
𝜃1 =
1
𝑛2
∑[𝜃0 + 𝐼𝜃0
−1𝑙𝜃0,Λ̂
∗ (𝑌𝑖)]
𝑛2
𝑖=1
+
1
√𝑛2
𝑂𝑝(1) 
Here 𝐼𝜃0
−1 =
1
𝑛2
∑ 𝛿𝑖 [
𝛴𝑗∈𝑅𝑖[exp
(𝜃0𝐼1𝑗)𝐼𝑗
2]
𝛴𝑗∈𝑅𝑖
(exp(𝜃0𝐼1𝑗))
− (
𝛴𝑗∈𝑅𝑖
[𝐼1𝑗 exp(𝜃0𝐼1𝑗)]
𝛴𝑗∈𝑅𝑖
(exp(𝜃0𝐼1𝑗))
)
2
]
𝑛2
𝑖=1  is the inverse of 
information matrix.  
𝑙𝜃0,Λ̂
∗ (𝑌𝑖) = 𝛿𝑖 {𝐼1𝑖 −
𝛴𝑗∈𝑅𝑖(𝐼1𝑗 𝑒𝑥𝑝(𝜃0𝐼1𝑗))
𝛴𝑗∈𝑅𝑖(𝑒𝑥𝑝(𝜃0𝐼1𝑗))
}
− 𝑒𝑥𝑝(𝜃0𝐼1𝑖) ∑ {𝛿𝑘 [
𝐼1𝑖
𝛴𝑗∈𝑅𝑘(𝑒𝑥𝑝(𝜃0𝐼1𝑗))
−
𝛴𝑗∈𝑅𝑘(𝐼1𝑗 𝑒𝑥𝑝(𝜃0𝐼1𝑗))
(𝛴𝑗∈𝑅𝑘(𝑒𝑥𝑝(𝜃0𝐼1𝑗)))
2]}
𝑡𝑘≤𝑡𝑖
 
is the efficient score function for subject 𝑖.  
 Meanwhile, we obtain the log hazard ratio ?̂? from historical data and control data 
of RCT using IPW Cox model. 
𝐼0√𝑛1(?̂? − 0) = 𝐼0√𝑛1?̂? =
1
√𝑛1
∑𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑖)
𝑛1
𝑖=1
+ 𝑂𝑝(1) 
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?̂? =
1
𝑛1
∑[𝐼0
−1𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑖)]
𝑛1
𝑖=1
+
1
√𝑛1
𝑂𝑝(1) 
The information matrix 𝐼0 =
1
𝑛1
∑
1
𝜋𝑖
𝛿𝑖 [
𝛴𝑗∈𝑅𝑖
𝐼1𝑗
2
𝜋𝑗
𝛴𝑗∈𝑅𝑖
1
𝜋𝑗
− (
𝛴𝑗∈𝑅𝑖
𝐼1𝑗
𝜋𝑗
𝛴𝑗∈𝑅𝑖
1
𝜋𝑗
)
2
]𝑛1𝑖=1 . 𝜋𝑗 = Pr(𝐼2𝑗 = 1|𝐗𝑗) is 
the propensity score for being in group C. Λ̂𝑝 is the estimated baseline hazard function 
from IPW Cox model. 
Then we use the linear combination of 𝜃1 and ?̂? to construct the unbiased estimate 
𝜃2 = 𝜃1 + 𝑎 ⋅ ?̂?. To minimize the variance of 𝜃2, we have 
𝑉𝑎𝑟(𝜃2) = 𝑉𝑎𝑟(𝜃1 + 𝑎?̂?) 
= 𝑉𝑎𝑟(𝜃1) + 2𝑎𝐶𝑜𝑣(𝜃1, ?̂?) + 𝑎
2𝑉𝑎𝑟(?̂?) 
Let 𝑎∗ = −
𝐶𝑜𝑣(?̂?1,𝑝)
𝑉𝑎𝑟(𝑝)
. We simply use 𝜃2 for 𝜃2|𝑎∗. Then we have 
 𝑉𝑎𝑟(𝜃2) = 𝑉𝑎𝑟(𝜃1) −
𝐶𝑜𝑣(𝜃1, ?̂?)
2
𝑉𝑎𝑟(?̂?)
= (1 − 𝜌2)𝑉𝑎𝑟(𝜃1) ≤ 𝑉𝑎𝑟(𝜃1) (13)  
Here 𝜌 =
𝑐𝑜𝑣(?̂?1,?̂?)
√𝑉𝑎𝑟(?̂?1)𝑉𝑎𝑟(𝑝)
. The larger 𝜌2 is, the more efficient 𝜃2 is. 
 
𝐶𝑜𝑣(𝜃1, ?̂?) = 𝐶𝑜𝑣 (
1
𝑛2
∑[𝜃0 + 𝐼𝜃0
−1𝑙𝜃0,Λ̂
∗ (𝑌𝑖)]
𝑛2
𝑖=1
,
1
𝑛1
∑[
1
𝜋
∗ 𝐼0
−1𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑖)]
𝑛1
𝑖=1
) 
= 𝐶𝑜𝑣 (
1
𝑛2
∑ [𝐼𝜃0
−1𝑙𝜃0,Λ̂
∗ (𝑌𝑚)]
𝑛𝑇+𝑛𝐶
𝑚=1
,
1
𝑛1
∑ [
1
𝜋
∗ 𝐼0
−1𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑙)]
𝑛𝐶+𝑛𝐻
𝑙=1
) 
=
1
𝑛1𝑛2
∑ ∑ 𝐶𝑜𝑣 (𝐼𝜃0
−1𝑙𝜃0,Λ̂
∗ (𝑌𝑚),
1
𝜋
∗ 𝐼0
−1𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑙))
𝑛𝐶+𝑛𝐻
𝑙=1
𝑛𝑇+𝑛𝐶
𝑚=1
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=
𝐼𝜃0
−1
𝑛1𝑛2
[∑∑𝐶𝑜𝑣 (𝑙𝜃0,Λ̂
∗ (𝑌𝑗),
1
𝜋
∗ 𝑙𝑝,Λ̂𝑝
∗ (𝑌𝑙))
𝑛𝐶
𝑙=1
𝑛𝐶
𝑗=1
] 𝐼0
−1 
=
𝑛𝐶
𝑛1𝑛2
𝐼𝜃0
−1 [𝐶𝑜𝑣 (𝑙𝜃0,Λ̂
∗ (𝑌𝐶),
1
𝜋
∗ 𝑙𝑝,Λ̂𝑝
∗ (𝑌𝐶))] 𝐼0
−1 
(14)  
𝑌𝐶  is the response of subjects from group C. Also we can get 
𝑉𝑎𝑟(?̂?) =
1
𝑛1
𝐼0
−1𝑉𝑎𝑟 [𝑙?̂?,Λ̂𝑝
∗ (𝑌𝐻)] 𝐼0̃ 
Here 𝑌𝐻 is response of the subject from group H. Based on (14), we could calculate 𝑎∗  
and 𝜃2 with more efficiency gain.     
 
3.3 Simulation  
 We carried out a simulation study to evaluation the performance of IPW 
estimate  𝜃2 especially the efficiency gain in dealing with time-to-event response. With 
the following steps, we simulated the dataset.  
1. Simulate covariate 𝐗 
 𝑋1~Βeta(𝛼, 𝛽),  (𝑋2, 𝑋3, 𝑋4)~𝑁((0,0,0)
𝑇 , 𝐈𝟑). 
2. Simulate the propensity score (PS) 
 𝑒 = Pr(𝐼1 𝑜𝑟 𝐼2 = 1) = 𝑋1~Βeta(𝛼, 𝛽). 𝑒 denotes the probability of being in 
RCT. 
3. Simulate the group indicator 𝐴 
 𝐴~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑝 = (
2
3
𝑒,
𝑒
3 
, 1 − 𝑒)). In RCT, we set 
𝑛𝑇
𝑛𝐶
= 2 to mimic the 
proportion of patients in ALS study. PS for group T, C and H is 
2
3
𝑒, 
1
3
𝑒 and 1 − 𝑒 
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respectively (see Table 20). Therefore, in group T, 𝑒~Βeta(𝛼 + 1, 𝛽); in group C, 
𝑒 ~Βeta(𝛼 + 1, 𝛽); in group H, 𝑒 ~Βeta(𝛼, 𝛽 + 1). 
Table 20 Multinomial distribution of group indicator 𝐴 
Group T C H 
𝐴 1 2 3 
PS 
2
3
𝑒 
1
3
𝑒 1 − 𝑒 
 
4. Simulate the survival time 𝑆.  
 In group C, let 𝑆~exp (
1
𝛽𝐶
), where  𝛽𝐶 =
𝑙𝑛2
𝑇𝑚𝑒𝑑
𝐶 . 𝑇𝑚𝑒𝑑
𝐶 = 20.5 is the median survival 
time of group C. In group T: 𝑆~exp (
1
𝛽𝑇
), where  𝛽𝑇 =
𝛽𝐶
𝐻𝑅
. Hazard ratio 𝐻𝑅 = 0.7 for 
group T v.s. C in RCT. Then we used Gaussian copula (parameter 0.3) to get the joint 
distribution of (𝑆, 𝑒) based on distribution of 𝑆 and 𝑒 in group C and T respectively. 
Therefore we obtained the conditional distribution (𝑆|𝑒). With PS 𝑒 generated in 
previous step, we generated 𝑆. In group H we generated 𝑆 using the same conditional 
distribution (𝑆|𝑒) as group C, since their distribution should be the same given the same 
PS.  
5. Simulate censoring time 𝐶  
 𝐶~𝑈𝑛𝑖𝑓𝑜𝑟𝑚[0,12] + 24. We mimic the ALS study in which patients are 
uniformly enrolled within 12 months and followed 24 month at most. 
6. Survival time 𝑇 with right censoring 𝑇 = min(𝑆, 𝐶). 𝛿 = 1 indicate an event. 
 We have 2 scenarios with different parameters of Beta distribution: 𝛼 = 4, 𝛽 =
16; 𝛼 = 12, 𝛽 = 8. When 𝛼 = 4, 𝛽 = 16, we mimic the real situation with more 
historical data involved. The proportions of # of subjects in group T/C/H are 13.3%, 6.7% 
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and 80.0%, respectively. When 𝛼 = 12, 𝛽 = 8, we had less historical data available. The 
proportions of # of subjects in T/C/H are 40%, 20% and 40%, respectively. In each 
scenario, we simulated 1000 MC datasets, each with 1000 subjects. 
 
3.4 Results 
 For the estimation process, we used logistic regression (assuming that model is 
correctly specified) to obtain the estimated the PS ?̂?. Then ?̂? was used for the estimation 
of 𝜃2. To evaluate the impact of the logistic regression model to our approach, we created 
another estimate ?̃?2 which use the true PS during the whole estimation. The simulation 
results are as following. 
Table 21 Results for scenario 1 
 Mean Bias SD MC SD MSE Coverage Prob 
𝜃1 -0.3657 -0.0091 0.1895 0.1888 0.0357 95.50% 
𝜃2 -0.3644 -0.0077 0.1454 0.1386 0.0193 96.00% 
?̃?2 -0.3651 -0.0084  0.1394 0.0195  
 
Table 22 Results for scenario 2 
 Mean Bias SD MC SD MSE Coverage Prob 
𝜃1 -0.3503 0.0064 0.1090 0.1036 0.0108 96.10% 
𝜃2 -0.3546 0.0021 0.0857 0.0821 0.0067 95.90% 
?̃?2 -0.3548 0.0018  0.0839 0.0070  
 
 The truth of  𝜃 = l𝑛(𝐻𝑅) = l𝑛(0.7) = −0.3567. In both scenarios (see Table 21 
and Table 22), the MSE of 𝜃2 is much smaller than that of 𝜃1 and the coverage 
probability of 𝜃2 is close to the nominal level. The performance of ?̃?2 is very similar as 
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𝜃2, which shows the logistic regression model for PS 𝑒 has little impact on the IPW 
estimate 𝜃2. 
 
3.5 Discussion 
Our simulation results show that 𝜃2 is an efficient estimate of the treatment effects 
from RCT. The information borrowed from historical data could greatly improve the 
precision of the estimation. We get a smaller SD and MSE by utilizing the historical 
control data in the approach. The coverage probability is close to nominal level. 
When applying the IPW estimates, we might think these two ways. 1). Before the 
RCT with the chosen historical control data, we could pre-design the sample size of RCT. 
Since 𝑉𝑎𝑟(𝜃2) = (1 − 𝜌
2)𝑉𝑎𝑟(𝜃1), with some assumption of  𝜌 =
𝑐𝑜𝑣(?̂?1,ℎ̂)
√𝑉𝑎𝑟(?̂?1)𝑉𝑎𝑟(ℎ̂)
, we 
could have an appropriate estimated variance of the log hazard ratio (effect size), which 
is often critical to the sample size calculation. 2). After the RCT, we could use the IPW 
approach to analyze the RCT data together with historical control data to obtain an 
unbiased, more efficient estimate for the treatment effect from RCT. 
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CHAPTER 4. THE ASSOCIATIONS OF DRUGS WITH ACUTE MYOCARDIAL 
INFARCTION: BIAS CORRECTION, GLOBAL PROFILING AND INFERENCE ON 
INDIVIDUAL DRUG 
4.1 Background 
 In typical non-randomized studies to investigate drug-outcome associations, risk 
measures are calculated based on models adjusting for an extended list of possible 
confounders. Many such studies are conducted in electronic health records databases 
(EHR) because of the wide adoption and availability of EHRs, and their population-wide 
and longitudinal coverage of patients. It has been recognized that EHRs are created for 
routine clinical care and administrative purposes but not for research, and thus they may 
harbor database biases due to, for example, failure or incomplete capture of exposure and 
covariates, hindering accurate estimations of causal effects. More likely than not, such 
database biases exist, hence the conventional estimate of the strength of a drug-outcome 
association, for example, from regressions, or even from more sophisticated propensity-
score based methods, may still be biased, leading to attenuated or exaggerated association 
assessment. In addition, bias could be introduced due to model mis-specifications and 
compound the distortion of the estimate of the drug-outcome association. Either error 
causes public health concerns: Missing a harmful drug-outcome association can place 
patients at risk of adverse events, and exaggeration of drug-outcome association can deter 
patients from taking beneficial drugs. For example, previous epidemiologic studies 
suggested that estrogen plus progestin therapy prevented coronary heart disease, but a 
definitive, prospective randomized trial, [37], found harm of hormone therapy (hazard 
ratio 1.29 over placebo). The study stopped prematurely because an excessive risk of 
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invasive breast cancer was found associated with hormone replacement therapy, contrary 
to findings of no association from previous epidemiologic studies [38]. 
 The database/model bias (henceforth the bias) could be characterized by a 
collection of drug-outcome association estimates from drugs which are known to be 
unrelated to the outcome events. For instance, the empirical distribution (Efron [39]) of 
risk estimates of these drugs can serve an characterization of the bias beyond what has 
been controlled in the analysis. The mean of such a distribution captures the bias due to 
limitations of the database or analytical methods. The idea of empirical nulls has been 
used in the analysis of EHR data (Schuemie, Ryan [40]). However, the previous focus in 
those applications has been on hypothesis testing rather than estimation. In a large EHR, 
accurate estimation of risk is much more prominent and relevant than hypothesis testing 
as the very magnitude of the strength is critical for decision-making. In addition, the 
characterization of estimation uncertainty by conventional frequentist method (e.g. 
confidence intervals) suffers from an unnatural interpretation (Diamond and Kaul [41]). 
Bayes inference offers an alternative method with heuristically appealing interpretation 
on estimation uncertainty using posterior distributions, particularly when the prior is a 
tangible and physically well-defined population (e.g. risk measures of all drugs for a 
given outcome). Along this line, empirical Bayes approach offers a reasonable solution 
(Robbins [42]), where the prior distribution is estimated from the data. The empirical 
Bayes approach has two extra advantages. First, there is a gain in accuracy for point 
estimate through borrowing information from other units (Efron [39]). Second, the prior 
distribution itself offers important knowledge on the state of the global drug-outcome 
associations.     
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 In this paper, we report an analysis strategy that addresses two issues in 
pharmaco-epidemiology studies: bias reduction and precision improvement. We will use 
the empirical null distribution to correct bias and a new Bayes deconvolution method for 
an empirical Bayes inference. We focus our interest on a specific outcome, acute 
myocardial infarction (AMI) in a standardized subset of state-wise database. Our method 
represents a general strategy for future studies of drug-outcome association for a wide 
range of diseases.  
 In the following sections, we will first describe components of our method 
including data source, a self-controlled case series method for the estimation of incidence 
risk ratio of a given drug, a bias calibration procedure and a Bayes deconvolution method 
to estimate the prior distribution of the true associations for all drugs. The method is then 
applied to studying drug association with AMI. Furthermore, we conduct a simulation 
study to evaluate the performance of the method. Finally, we conclude the article with 
discussions. 
 
4.2 Methods 
4.2.1 Data source 
The study is conducted using existing data, the Regenstrief Institute’s electronic 
health records from 1/1/2004 to 12/31/2009 in the common data model,[43] which 
contains de-identified healthcare data of approximately 2.2 million unique patients from 
INPC. The common data model is a representative, longitudinal sample of the Indiana 
population in terms of prescriptions, claims, diagnoses and labs. We restrict our analysis 
 48 
to patients of 40 years and older because of data use agreement with a certain insurance 
payer.  
In the calculation of the risk ratio of AMI for each drug, the exposure period and 
the events of interest are defined as follows. We use drug eras in the “drug era” table in 
the common data model to define the exposure to a drug. A drug era consists of drug 
prescriptions, dispenses or refill claims that are recorded in successive periods within 30 
days of each other and are combined to form one continuous period.[44] We added 90 
days to the end of a drug era for the capture of AMI events for its possible lingering risk 
effect. The drug exposure is the collection of the drug eras. AMI is defined as the 
occurrence of at least one narrow diagnostic code ICD-9-CM 410* “Acute myocardial 
infarction” with either at least one diagnostic procedure code within 30 days prior to 
diagnostic code or at least one therapeutic procedure code within 60 days after the 
diagnostic code.  
4.2.2 Self-controlled case series method  
We used a self-controlled case series method (SCCS[45]) to estimate the 
incidence risk ratios with respect to AMI for all drugs with a sample size at least 10. 
SCCS is an intuitive method in controlling any known or unknown confounding as it uses 
each case (patient with the event under investigation) as his or her own control. It can be 
used to assess the association between an acute event and a transient exposure using cases 
only, without the need of a control group[45, 46].  The method estimates the ratio of the 
rate of events (number of events per unit time) in the exposure periods of a drug and the 
rate of events in the non-exposure periods during the entire observation period for a 
patient. A less than 1 rate ratio suggests that the drug has protective effect (or negative 
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association), whereas a rate ratio greater than 1 suggests a harmful effect (or positive 
association). If there were a positive association between a drug and a condition, one 
would expect higher event rates for the on-drug eras. 
SCCS is appealing in database studies because of two major advantages.[46]  
First, it uses cases only and therefore is economical in terms of both time and cost.  
Second, it elegantly controls for both measured and unmeasured time-invariant 
confounders by using each subject as his own control, without explicitly modeling and 
adjusting confounders. 
4.2.3 Bias calibration 
Let 𝑅𝑅 denote the true incidence risk ratio of AMI for a drug, and 𝑅?̂? denote the 
estimated risk ratio. Correspondingly, 𝜃 = ln𝑅𝑅 and 𝜃 = ln𝑅?̂? are the logarithms of the 
true and the estimated risk ratios respectively. Applying SCCS to the INPC data, we 
obtained the point estimates of 𝜃 and its standard error 𝜎 for each drug. 
The bias for the estimation of the association of a drug with AMI Δ is defined as 
𝐸(𝑍) −
𝜃
𝜎
, where 𝑍 =
?̂?
𝜎
. Although we cannot identify the bias for each individual drug, it 
is possible to estimate the average of  Δ from a set of drugs that are known to have no 
associations with AMI. Such an averaged bias can be used to correct risk ratio estimate to 
reduce bias. OMOP had identified 66 drugs as having no association with AMI (negative 
controls; see the table in Appendix  for drug names), using information from the Food 
and Drug Administration (FDA) drug labels, literature, and randomized clinical trials to 
establish the drug-outcome associations and non-associations (Ryan, Schuemie [47]). The 
Z-statistics from these negative controls ideally would follow a standard normal 
distribution if there was no bias. The mean of Z-statistics of the negative controls ?̅?0 in 
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general offers some evidence towards the existence of bias and we use it for the 
estimation of the average (across drugs) of 𝛥.   
4.2.4 Bayes deconvolution method  
Let  𝑝(. ) and  ?̂?(. ) denote the probability density function of 𝑅𝑅 and its estimate 
respectively. Our objectives were to compute (a) ?̂?(𝑅𝑅) that could then be used to 
estimate the proportions of drugs in the database with various strengths of association 
with AMI, and to derive (b) ?̂?(𝑅𝑅|𝑍∗, 𝜎∗, ?̂?∗), the posterior distribution of 𝑅𝑅 for a new 
drug with summary data (𝑍∗, 𝜎∗) and the estimated bias ?̂?∗, needed in making inference 
on the association of the new drug with AMI. 
We considered the following model 
 
𝑍 =
𝜃
𝜎
=
𝜃
𝜎
+ 𝜖 + 𝛥 =
𝑓(𝜎) + 𝛿
𝜎
+ 𝜖 + 𝛥, 𝜖~𝑁(0,1)         (15)  
where we omit subscript (for drug) for simplicity of presentation. The main model 
assumption is that RR on the logarithm scale (𝜃) can be expressed as some function f of 𝜎 
plus the random effect 𝛿 that has a marginal distribution 𝑔(𝛿). Further we assumed that 𝛿 
and 𝜎 are independent. Since 𝜖 represents error due to sampling subjects, it is 
independent of (𝜎, 𝛿). A scatter plot of 𝜃 and 𝜎 (see Figure 1) exhibits a quadratic 
relationship between 𝜃 and 𝜎, suggesting a model below: 
 𝑓(𝜎) = 𝛽1𝜎 + 𝛽2𝜎
2. (16)  
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Figure 1 Scatter plot and ordinary least square fit of  ?̂? and 𝝈 
 
Note that the intercept for 𝑓(𝜎) is absorbed in the distribution of 𝛿. We now have 
 𝑍 =
𝛿 + 𝛽1𝜎 + 𝛽2𝜎
2
𝜎
+ 𝜖 + 𝛥, 𝜖~𝑁(0,1) 
(17)  
We then applied Efron’s Bayes deconvolution method (Efron [48]). Specifically, we 
treated 𝛥 as fixed and plugged in ?̅?0 estimated from the negative controls. We assumed 
that the probability density function 𝑔(𝛿) belongs to a class of natural cubic splines. This 
class is fairly rich and covers or approximates most of the distributions in practice. It 
strikes a balance between nonparametric methods with strong robustness but slow 
convergence rate and parametric methods with root-N convergence rate but poor 
robustness. Akaike Information Criterion (AIC) and Bayesian Information Criterion 
(BIC) were used to select the degree of freedom of the natural cubic spline. To estimate 
?̂?(𝛿), we applied the maximum likelihood estimation (MLE) to summary data (𝑍𝑖 , 𝜎𝑖) 
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𝑖 = 1, 2, … ,𝑁 as described by Efron [48]. The estimated ?̂?(𝛿) was then used to compute 
?̂?(𝑅𝑅) and  ?̂?(𝑅𝑅|𝑍∗, 𝜎∗, ?̂?∗) (Appendix for details).  
 
4.3 Results 
 There are 465 drugs in the database suitable for SCCS analysis. Out of the 465 
drugs, 59 drugs were excluded through a literature review as they are either used to 
prevent or to treat AMI. Two more drugs were excluded due to numerical instability. We 
kept the remaining 404 drugs for further analysis. The median and the interquartile range 
of the sample size of these drugs are 89 and 218 respectively. 
 We calculated the Z-statistics 𝑍𝑖 and standard error estimate 𝜎𝑖, 𝑖 = 1, 2, … , 404. 
Among 66 true AMI negatives drugs (Ryan, Schuemie [47]), there are 39 drugs evaluable 
in the database. The mean of the Z-statistics of these drugs ?̅?0 = 0.31, which is an 
estimate of the mean of the bias 𝛥 in the drug-AMI associations. A test of the null-bias 
hypothesis results in a p-value of 0.053, indicating some statistical evidence on the 
existence of bias. We carried out all remaining analysis with and without the bias 
correction. For the analysis with the bias correction, we corrected Z-statistics by 
subtracting 𝛺 from the original Z for all the drugs. Note that this procedure implies a 
constant bias for each drug, which may not hold in reality. Yet, drug-specific bias is not 
directly identifiable. In our simulation studies, we investigated the robustness of this 
procedure under the scenarios where the bias is not constant across drugs. 
 In Figure 2, we show the histogram of 𝑅?̂? for all 404 drugs, together with the 
estimated distribution of RR (?̂?(𝑅𝑅)) and 𝑅?̂? (?̂?(𝑅?̂?)). It is clear that ?̂?(𝑅𝑅) after bias 
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correction shifts towards the left with respect to ?̂?(𝑅𝑅) without bias correction. The mean 
(SD) of 𝑅𝑅 is 1.17(0.34) (without bias correction) and 1.05(0.32) (with bias correction). 
Figure 2 Histogram and the prior density of RR and RR̂ 
 
Based on ?̂?(𝑅𝑅), 95% of 𝑅𝑅𝑠 fall in [0.57,1.97] (without bias correction) and 
[0.43,1.79] (with bias correction). The probabilities of the included drugs having a risk 
ratio for AMI greater than 1, 1.5 and 2 (harmful effects) are 68.1%, 11.9%, 2.3% (without 
bias correction) and 51.5%, 7.0%, 1.4% (with bias correction). The probabilities of the 
included drugs having a risk ratio for AMI no greater than 1, 0.67 and 0.5 (null or 
protective effects) are 31.9%, 3.4% and 2.0% (without bias correction) and 48.5%, 6.4%, 
3.1% (with bias correction). See Table 23 for more details. 
 
  
5
4
 
 
Table 23 Drug-outcome association inference from the estimated marginal distribution of RR (?̂?(𝑅𝑅)) 
Bias 
Pr(𝑅𝑅 ≤ 𝑐) Pr(𝑅𝑅 > 𝑐) 
c = 1 c = 0.67 c = 0.5 c = 1 c = 1.5 c = 2 
Estimate 
(95%) 
Estimate 
(95%) 
Estimate 
(95%) 
Estimate 
(95%) 
Estimate 
(95%) 
Estimate 
(95%) 
0 
0.319 
[0.241,0.393] 
0.034 
[0.015,0.053] 
0.020 
[0.004,0.034] 
0.681 
[0.607,0.759] 
0.119 
[0.075,0.16] 
0.023 
[0.005,0.044] 
0.31 
0.485 
[0.402,0.551] 
0.064 
[0.037,0.093] 
0.031 
[0.014,0.047] 
0.515 
[0.449,0.598] 
0.070 
[0.0,0.101] 
0.014 
[0.002,0.034] 
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Since ?̂?(𝑅𝑅) was estimated from data, we would like to understand the level of 
uncertainty in estimating ?̂?(𝑅𝑅) and its impact on the estimated posterior distribution. 
From 500 bootstrap samples, we obtained the 95% confidence intervals (CIs) of ?̂?(𝑅𝑅) 
(Table 23). Combining results with and without bias correction with consideration of 
uncertainty, as high as 4.4% of the drugs have an RR>2 (upper limit of the 95% 
confidence interval for Pr(𝑅𝑅 > 2) without bias correction), or equivalently no more 
than 404*0.044=18 drugs are expected to have RR>2.   
Suppose we have a hypothetical new drug with the same point estimate 𝑅?̂?∗ and 
standard error estimates 𝜎∗ as drug “Aliskiren” (𝑅𝑅∗̂ = 2.19, 𝜎∗ = 0.345 so that 𝑍∗ =
2.27), we computed the posterior distribution (dash lines in Figure 3).  
Figure 3 Prior and posterior density of RR given RR̂∗ = 2.19, σ∗ = 0.345 
 
 From the posterior distribution, the mean (SD) of 𝑅𝑅 is 1.52(0.37) (without bias 
correction) and 1.36(0.34) (with bias correction). 95% credible region of 𝑅𝑅 is 
[1.00,2.46] (without bias correction) and [0.91,2.18] (with bias correction). The 
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frequentist 95% CI for 𝑅𝑅 is [1.11,3.74]. So the precision gain is 45% (without bias 
correction) and 52% (with bias correction) with the understanding that the two 
confidence intervals have different interpretations. A nice feature of the posterior 
distribution is its interpretation. Unlike full Bayesian method where the posterior 
distribution is not connected to any tangible population, the posterior distribution of our 
method represents the distribution of RR among all drugs with 𝑅?̂?∗ = 2.19 
and 𝜎∗=0.345. In other words, the posterior distribution is calibrated with respect to 
𝑝(𝑅𝑅), subjects to potential bias due to estimating ?̂?(𝑅𝑅) (our simulation studies show 
that such a bias tends to be negligible for the data analyzed in this article) We will call the 
population of drugs with 𝑅?̂?∗ = 2.19 and 𝜎∗=0.345 the reference population of the new 
drug.  
 Table 24 shows the posterior distribution evaluated at 1, 1.5, and 2. It can be seen 
that 97.3%, 43.6% and 9.7% of the drugs in the reference population have a true 𝑅𝑅 >
1, 1.5 and 2 (harmful effects). Similarly, 2.7%, 0% and 0% of the drugs in the reference 
population have a true 𝑅𝑅 ≤ 1, 0.67 and 0.5 (protective effects). This is a particularly 
appealing interpretation of estimation uncertainty as it is natural and simple. The bias 
correction reduces the proportions to 91.2%, 26.7% and 4.9% for 𝑅𝑅 >  1, 1.5 and 2. 
Because we have limited number of drugs, the estimates of the posterior distribution 
demonstrate some level of variations as shown by the CIs in Table 24.
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Table 24 Drug-outcome association inference from the posterior distribution (p̂(RR|Z∗ = 2.272, σ∗ = 0.345, Δ̂∗)) 
Bias 
Pr(𝑅𝑅 ≤ 𝑐) Pr(𝑅𝑅 > 𝑐) 
c = 1 c = 0.67 c = 0.5 c = 1 c = 1.5 c = 2 
Estimate (95%) 
Estimate 
(95%) 
Estimate 
(95%) 
Estimate (95%) Estimate (95%) Estimate (95%) 
?̂?∗ = 0 
0.027 
[0.013,0.045] 
0 (NA) 0 (NA) 
0.973 
[0.955,0.987] 
0.436 
[0.304,0.524] 
0.097 
[0.024,0.157] 
?̂?∗ = 0.31 0.088 [0.056,0.14] 0 (NA) 0 (NA) 0.912 [0.86,0.944] 
0.267 
[0.156,0.346] 
0.049 
[0.007,0.096] 
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4.4 Simulation 
 We carried out two simulation studies. In simulation 1, we evaluated the level of 
accuracy in estimating 𝑔(𝛿) and its impact on ?̂?(𝑅𝑅|𝑍∗, 𝜎∗), where we assumed there 
was no bias, i.e. 𝛥 ≡ 0, in data generation and in estimation. It is sufficient to study the 
case of 𝛥 ≡ 0 because we are primarily interested in how estimation of 𝑔(𝛿) affects 
posterior inference. In simulation 2, we assessed the combined impact of bias correction 
and the estimation of 𝑔(𝛿) on the inference based on ?̂?(𝑅𝑅|𝑍∗, 𝜎∗, ?̂?∗). In this 
simulation, we generated bias for each drug according to some distribution during data 
generation and assumed ?̂? = 0.31 during estimation; the posterior distribution was 
conditioned on ?̂?∗ = 0 or 0.31.  
Simulation 1: 
We simulated 500 Monte Carlo (MC) datasets. Each dataset included (𝑍𝑖 , 𝜎𝑖), 𝑖 =
1, 2, … , 404, generated by equation (3) with 𝛥 ≡ 0 (setting 1), where 𝛽1, 𝛽2 and 𝑔 were 
set at the estimated values of section 0, and the empirical distribution of 𝜎 among the 404 
drugs was assumed to be the true distribution of 𝜎. Each MC data set was used to 
estimate 𝛽1, 𝛽2 and 𝑔. In addition, we generated 𝑍𝑗
∗, 𝑗 = 1, 2, 3, for three exemplar new 
drugs whose relative risks are to be inferred from each MC data, with specific true risk 
ratio 𝑅𝑅𝑗
∗, standard error 𝜎𝑗
∗, and no bias 𝛥∗ = 0. Here 𝑅𝑅1
∗, 𝑅𝑅2
∗ and 𝑅𝑅3
∗ were chosen to 
be close to the mean of ?̂?(𝑅𝑅) (with bias correction), the mean plus one standard 
deviation of ?̂?(𝑅𝑅) and the mean minus one standard deviation: 𝑅𝑅1
∗ = 1, 𝜎1
∗ = 0.120; 
𝑅𝑅2
∗ = 1.387, 𝜎2
∗ = 0.202; 𝑅𝑅3
∗ = 0.726, 𝜎3
∗ = 0.121.  
We applied the maximum likelihood estimation (MLE) to summary data (𝑍𝑖, 𝜎𝑖) 
𝑖 = 1, 2, … , 404 as described in Section 1.4 and obtained ?̂?1, ?̂?2 and ?̂?, which in turn were 
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used to estimate posterior ?̂?(𝜃|𝑍𝑗
∗, 𝜎𝑗
∗). Furthermore, the true posterior 𝑝(𝜃|𝑍𝑗
∗, 𝜎𝑗
∗) was 
calculated based on true 𝛽1, 𝛽2 and 𝑔. 
Figure 4(a) shows the mean of the estimates ?̅?(𝛿𝑘) =
∑ ?̂?𝑠(𝛿𝑘)
500
𝑠=1
500
 in black and the 
true 𝑔(𝛿) in red at a set of grid points 𝛿𝑘 with a grid spacing of 0.01 (𝑘 = 1, 2,⋯ , 261) . 
The vertical dash bars represent ?̅?(𝛿𝑘) ± 𝑠𝑑(?̂?(𝛿𝑘)). The plot shows that ?̂? is essentially 
unbiased at most locations except the neighborhood of the mode.  
Figure 4 Density  ?̅? ± 𝑠𝑑 from 3 simulation settings compared with the true density g 
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4(a): 𝛥 ≡ 0 for both data generation and estimation. 
4(b): 𝛥~𝑁(0.31, 𝜎2), where 𝜎2 = 0.13. 𝑔 is estimated by assuming a constant bias ?̂? ≡
0.31. 
4(c): 𝛥 ~𝑁(0.31, 4𝜎2), where 𝜎2 = 0.13. 𝑔 is estimated by assuming a constant bias 
?̂? ≡ 0.31. 
To evaluate the performance of the estimated posterior distribution, we studied 
the coverage probability of the 95% credible region (CR), which is defined as the average 
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(over Monte Carlo simulations) probability mass between the 2.5 and 97.5 percentiles of 
?̂?(𝑅𝑅|𝑍𝑗
∗, 𝜎𝑗
∗) under 𝑝(𝑅𝑅|𝑍𝑖
∗, 𝜎𝑖
∗). As shown in Table 25, the coverage probabilities for 
setting 1 are close to the nominal level.  
Table 25 Coverage probability of the posterior distribution when Δ̂∗ = Δ∗ 
Setting Δ∗ Δ̂∗ 
Coverage probability 
𝑅𝑅1
∗ = 1, 
𝜎1
∗ = 0.120 
𝑅𝑅2
∗ = 1.387, 
𝜎2
∗ = 0.202 
𝑅𝑅3
∗ = 0.726, 
𝜎3
∗ = 0.121 
1 0.00 0.00 95.2% 95.3% 94.6% 
2 0.31 0.31 94.9% 94.9% 94.1% 
3 0.31 0.31 93.9% 93.5% 91.6% 
 
We summarized the bias and mean square error (MSE) of 𝑅?̃?𝑗
∗, i.e. the mean of 
?̂?(𝑅𝑅|𝑍𝑗
∗, 𝜎𝑗
∗). For comparison, we also computed the bias and the MSE of 𝑅?̂?𝑗
∗ (𝑅?̂?𝑗
∗ =
exp(𝑍𝑗
∗𝜎𝑗
∗), which is the conventional frequentist estimate. As shown in Table 26 under 
setting 1, the bias of 𝑅?̃?𝑗
∗ is acceptable and larger than that of 𝑅?̂?𝑗
∗ since 𝑅?̃?𝑗
∗ is a 
shrinkage estimator[49]. The MSE of 𝑅?̃?𝑗
∗ is smaller than that of 𝑅?̂?𝑗
∗ for 𝑗 = 1, 2 because 
of the precision gain of 𝑅?̃?𝑗
∗. The MSE of 𝑅?̃?3
∗ is greater than that of 𝑅?̂?3
∗ since 𝑅?̂?3
∗ 
already has a small standard error and the bias of the estimate dominates the MSE.  
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Table 26 Bias and MSE of RR̃j
∗ from the posterior distribution when Δ̂∗ = Δ∗ 
Setting 𝛥∗ Δ̂∗ 
Bayes posterior estimate 𝑅?̃?𝑗
∗ 𝑅?̂?𝑗
∗ 
Bias MSE Bias MSE 
𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 
1 0.00 0.00 0.025 -0.119 0.096 0.094 0.194 0.117 
0.011 0.02 0.005 0.123 0.272 0.092 2 0.31 0.31 0.024 -0.111 0.089 0.096 0.195 0.113 
3 0.31 0.31 0.022 -0.086 0.071 0.102 0.200 0.103 
For reference, we have the true risk ratio and their standard error as following: RR1
∗ = 1, σ1
∗ = 0.120; RR2
∗ = 1.387, σ2
∗ = 0.202; 
RR3
∗ = 0.726, σ3
∗ = 0.121. 
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Simulation 2: 
In this simulation, data were generated the same way as in Simulation 1 except 
that a bias distribution was added. We considered two settings of bias distribution: 
𝛥~𝑁(0.31, 𝜎2) (setting 2) and 𝛥 ~𝑁(0.31, 4𝜎2) (setting 3), where 𝜎2 = 0.13. Here the 
value 0.13 was chosen because the variance of the bias should be equal to the variance of 
Z statistics for the negative controls (1.13) minus the variance in the absence of bias (1). 
For each of the three new drugs, we set the true bias at five values, 𝛥∗ = 0.31 −
2𝜎, 0.31 − 𝜎, 0.31,0.31 + 𝜎, and 0.31 + 2𝜎.  
?̂?1, ?̂?2 and ?̂? were estimated as in Section 1.4 by assuming a constant bias ?̂? ≡
0.31. The true posterior 𝑝(𝜃|𝑍𝑗
∗, 𝜎𝑗
∗, 𝛥∗) was based on true 𝛽1, 𝛽2 and 𝑔, and the true bias 
𝛥∗; the estimated posterior ?̂?(𝜃|𝑍𝑗
∗, 𝜎𝑗
∗, ?̂?∗) was computed using ?̂?1, ?̂?2 and ?̂?, and an 
assumed bias ?̂?∗, 0 or 0.31. Thus, in simulation 2, the assumed bias for each drug during 
estimation of model parameters and computation of posterior distribution is incorrect. 
When the assumed bias is 0.31, it at least matches the average bias. When the assumed 
bias is 0, it does not. Simulation 2 allows us to evaluate the impact of incorrect 
specification of the bias (together with the estimation of model parameters) on the 
posterior inference. 
We assessed the estimation of 𝑔(𝛿) when an incorrect constant bias correction 
was used (Figure 4(b) and 4(c)). The plot shows that ?̂? is essentially unbiased at most 
locations except the neighborhood of the mode, the same feature as in Simulation 1. The 
95% CR is the average (over Monte Carlo simulations) probability mass between the 2.5 
and 97.5 percentiles of ?̂?(𝑅𝑅|𝑍𝑗
∗, 𝜎𝑗
∗, ?̂?∗) under 𝑝(𝑅𝑅|𝑍𝑖
∗, 𝜎𝑖
∗, 𝛥∗). When ?̂?∗ = 𝛥∗, as 
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shown in Table 25, the coverage probabilities for setting 2 and 3 are close to the nominal 
level, the same as setting 1. When ?̂?∗ ≠ 𝛥∗, as shown in Table 27, the coverage 
probabilities for setting 2 and 3 are greater than 90 % if the absolute difference between 
?̂?∗ and 𝛥∗ is small to moderate (less than 2𝜎). 
Table 27 Coverage probability of the posterior distribution when Δ̂∗ ≠ Δ∗ 
Setting Δ∗ Δ̂∗ 
Coverage probability 
𝑅𝑅1
∗ = 1, 
𝜎1
∗ = 0.120 
𝑅𝑅2
∗ = 1.387, 
𝜎2
∗ = 0.202 
𝑅𝑅3
∗ = 0.726, 
𝜎3
∗ = 0.121 
2 -0.408 0.310 90.5% 92.0% 89.0% 
2 -0.408 0.000 94.3% 95.4% 93.1% 
2 -0.049 0.310 93.8% 94.3% 92.5% 
2 -0.049 0.000 95.0% 95.3% 94.1% 
2 0.310 0.000 93.5% 93.4% 93.0% 
2 0.669 0.310 93.6% 93.5% 93.5% 
2 0.669 0.000 89.6% 89.6% 89.8% 
2 1.028 0.310 90.0% 90.1% 90.7% 
2 1.028 0.000 83.2% 83.4% 84.1% 
3 -0.408 0.310 88.1% 90.6% 81.9% 
3 -0.408 0.000 92.8% 94.1% 88.6% 
3 -0.049 0.310 92.3% 93.1% 87.9% 
3 -0.049 0.000 94.0% 93.8% 91.9% 
3 0.310 0.000 92.8% 91.3% 92.7% 
3 0.669 0.310 92.8% 91.4% 92.8% 
3 0.669 0.000 88.8% 86.4% 90.9% 
3 1.028 0.310 88.9% 86.8% 91.3% 
3 1.028 0.000 81.9% 78.9% 86.3% 
 
We summarized the bias and MSE of 𝑅?̃?𝑗
∗, the mean of ?̂?(𝑅𝑅|𝑍𝑗
∗, 𝜎𝑗
∗, ?̂?∗). For 
comparison, we also computed the bias and MSE of 𝑅?̂?𝑗
∗, where 𝑅?̂?𝑗
∗ = exp((𝑍𝑗
∗ −
 ?̂?∗)𝜎𝑗
∗). When ?̂?∗ = 𝛥∗, as shown in Table 26, the bias and MSE of 𝑅?̃?𝑗
∗ in setting 2 and 
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3 have the same features as in setting 1. When ?̂?∗ ≠ 𝛥∗, both 𝑅?̃?𝑗
∗ and 𝑅?̂?𝑗
∗ are affected 
by the incorrect bias correction. When 𝛥∗ − ?̂?∗ > 0, the bias is under-corrected, pulling 
𝑅?̃?𝑗
∗ and 𝑅?̂?𝑗
∗ in the positive direction; When 𝛥∗ − ?̂?∗ < 0, the bias is over-corrected, 
pulling 𝑅?̃?𝑗
∗ and 𝑅?̂?𝑗
∗ in the negative direction.  
We are mainly concerned about drugs with harmful effects 𝑅𝑅∗ > 1, e.g. in the 
case of testing the second drug. The effect of incorrect bias correction for 𝑅?̃?2
∗ and 𝑅?̂?2
∗ 
and the shrinkage for 𝑅?̃?2
∗ are illustrated in Figure 5.  
Figure 5 Combined effects of bias correction and shrinkage estimation on the bias of RR̃2
∗  
compared with RR̂2
∗  
 
(a) 
 
 
(b) 
 When 𝛥∗ − ?̂?∗ > 0 (Figure 5(a)), the bias correction and shrinkage go in the 
opposite directions. Therefore the bias of 𝑅?̃?2
∗ is smaller than 𝑅?̂?2
∗’s (e.g. Table 28, 𝛥∗ =
0.31, ?̂?∗ = 0). When 𝛥∗ − ?̂?∗ < 0 (Figure 5(b)), the bias correction and shrinkage go in 
𝑅?̂?2
∗ Mean of ?̂?(𝑅𝑅)  𝑅𝑅2
∗ 𝑅?̃?2
∗ 
𝛥∗ − ?̂?∗ > 0,→ 
Shrinkage, ← 
𝑅?̂?2
∗ Mean of  ?̂?(𝑅𝑅) 𝑅𝑅2
∗ 𝑅?̃?2
∗ 
𝛥∗ − ?̂?∗ > 0,← 
Shrinkage, ← 
R
R 
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the same direction. Therefore the bias of 𝑅?̃?2
∗ is larger than 𝑅?̂?2
∗’s (e.g. Table 28, 𝛥∗ =
−0.049, ?̂?∗ = 0.31). 
 For the third drug with protective effect (𝑅𝑅∗ < 1), we illustrate the same 
phenomenon in Figure 6.  
Figure 6 Combined effects of bias correction and shrinkage estimation  
on the bias of RR̃3
∗  compared with RR̂3
∗  
 
(a) 
 
 
(b) 
 When 𝛥∗ − ?̂?∗ < 0 (Figure 6(a)), the shrinkage and the bias correction go in the 
opposite directions so that the bias of 𝑅?̃?3
∗ is larger than that of 𝑅?̂?3
∗ for most of the 
scenarios (e.g. Table 28, 𝛥∗ = −0.408, ?̂?∗ = 0). When 𝛥∗ − ?̂?∗ > 0 (Figure 6(b)), the 
shrinkage and the bias correction go in the same direction. Therefore the bias of 𝑅?̃?3
∗ is 
larger than that of 𝑅?̂?3
∗ (e.g. Table 28, 𝛥∗ = 0.31, ?̂?∗ = 0). When the shrinkage and the 
bias correction go in the opposite directions, the shrinkage could be so strong that it pulls 
𝛥∗ − ?̂?∗ < 0,← 
Mean of ?̂?(𝑅𝑅) 
𝑅𝑅3
∗ 𝑅?̃?3
∗ 𝑅?̂?3
∗ 
Shrinkage, → 
Mean of ?̂?(𝑅𝑅)  
𝑅𝑅3
∗ 𝑅?̃?3
∗ 
𝛥∗ − ?̂?∗ > 0,→ 
𝑅?̂?3
∗ 
Shrinkage, → 
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the 𝑅?̃?3
∗  to the other side of the true value, causing biases in 𝑅?̃?3
∗  and 𝑅?̂?3
∗ with opposite 
signs (e.g. Table 28, 𝛥∗ = −0.408, ?̂?∗ = 0.31). 
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Table 28 Bias and MSE of RR̃j
∗ from the posterior distribution when Δ̂∗ ≠ Δ∗ 
Setting Δ∗ Δ̂∗ 
Bayes posterior estimate 𝑅?̃?𝑗
∗ 𝑅?̂?𝑗
∗ 
Bias 𝑀𝑆𝐸 Bias MSE 
𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 𝑗 = 1 𝑗 = 2 𝑗 = 3 
2 -0.408 0.310 -0.039 -0.218 0.043 0.094 0.256 0.077 -0.072 -0.171 -0.056 0.133 0.29 0.101 
2 -0.408 0.000 -0.002 -0.143 0.072 0.089 0.201 0.098 -0.037 -0.092 -0.03 0.122 0.266 0.092 
2 -0.049 0.310 -0.008 -0.167 0.065 0.090 0.222 0.094 -0.031 -0.079 -0.026 0.121 0.264 0.091 
2 -0.049 0.000 0.030 -0.088 0.095 0.098 0.179 0.118 0.005 0.006 0.001 0.121 0.269 0.091 
2 0.310 0.000 0.063 -0.028 0.120 0.116 0.174 0.140 0.049 0.111 0.034 0.136 0.309 0.101 
2 0.669 0.310 0.058 -0.047 0.113 0.114 0.186 0.135 0.055 0.126 0.038 0.139 0.318 0.103 
2 0.669 0.000 0.098 0.039 0.145 0.141 0.195 0.164 0.095 0.224 0.068 0.163 0.383 0.12 
2 1.028 0.310 0.094 0.022 0.139 0.139 0.201 0.159 0.102 0.24 0.072 0.167 0.395 0.123 
2 1.028 0.000 0.135 0.112 0.172 0.173 0.238 0.189 0.143 0.345 0.103 0.199 0.48 0.146 
3 -0.408 0.310 -0.046 -0.208 0.022 0.102 0.257 0.071 -0.072 -0.171 -0.056 0.133 0.29 0.101 
3 -0.408 0.000 -0.009 -0.133 0.049 0.095 0.208 0.088 -0.037 -0.092 -0.03 0.122 0.266 0.092 
3 -0.049 0.310 -0.012 -0.150 0.045 0.096 0.223 0.085 -0.031 -0.079 -0.026 0.121 0.264 0.091 
3 -0.049 0.000 0.025 -0.070 0.075 0.102 0.190 0.106 0.005 0.006 0.001 0.121 0.269 0.091 
3 0.310 0.000 0.061 -0.003 0.101 0.120 0.192 0.128 0.049 0.111 0.034 0.136 0.309 0.101 
3 0.669 0.310 0.059 -0.016 0.097 0.120 0.200 0.125 0.055 0.126 0.038 0.139 0.318 0.103 
3 0.669 0.000 0.099 0.072 0.129 0.146 0.224 0.152 0.095 0.224 0.068 0.163 0.383 0.12 
3 1.028 0.310 0.097 0.061 0.125 0.146 0.227 0.149 0.102 0.24 0.072 0.167 0.395 0.123 
3 1.028 0.000 0.138 0.153 0.158 0.179 0.277 0.179 0.143 0.345 0.103 0.199 0.48 0.146 
For reference, we have the true risk ratio and their standard error as following: 𝑅𝑅1
∗ = 1, 𝜎1
∗ = 0.120; 𝑅𝑅2
∗ = 1.387, 𝜎2
∗ = 0.202; 
𝑅𝑅3
∗ = 0.726, 𝜎3
∗ = 0.121. 
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As shown in Table 28, the MSE of 𝑅?̃?𝑗
∗ is smaller than that of  𝑅?̂?𝑗
∗ for 𝑗 = 1, 2 
due to the precision gain. But in most of the cases for 𝑗 = 3, 𝑅?̃?3
∗ has a slightly larger 
MSE than 𝑅?̂?3
∗. Since 𝑅𝑅3
∗ has a small standard error, the precision gain of 𝑅?̃?3
∗ cannot 
offset its bias and lead to the slightly larger MSE. 
In summary, the simulation results show that the estimation of 𝑔(𝛿) is mostly 
accurate using our approach and that the true distribution of bias has little influence on it. 
All cases of 𝑅?̃?𝑗
∗ 𝑗 = 1, 2 have improved MSE through the precision gain. Although 𝑅?̃?3
∗ 
has a slightly inflated MSE in most of the cases, the drug has a protective effect and is of 
little safety concern. 
 
4.5 Discussion 
 In this chapter, we focused on obtaining the distribution of the risk ratios so that 
the strength and direction of the association with a given outcome can be properly 
assessed for a population of drugs and an individual drug in the future. Our strategy 
includes a bias correction procedure leveraging drugs known to have no association with 
the outcome, followed by an empirical Bayes procedure based on the bias corrected risk 
ratio estimates. 
 Typical approaches for risk identification include the following designs and 
corresponding analytical methods: SCCS, new-user cohort design, case control design, 
self-controlled cohort design, temporal pattern discovery, and others (Ryan, Stang [50]). 
The main attractive feature of SCCS is that it is self-controlled, in which the effects of 
any fixed covariates cancel out. But there are also some limitations of which we need to 
be aware.  
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 First, the validity of a risk ratio estimate by SCCS critically depends on the 
definitions of the outcome and the drug exposure. If a single event is mistakenly 
considered as multiple distinct events, e.g., subsequent treatment or management of an 
earlier AMI event are counted as multiple occurrences of AMI, such mistakes could lead 
to over- or under-estimation of the risk ratio. However, this can be overcome by 
considering the first event only for a patient. On the other hand, drug exposure could be 
under-captured since an EHR is by no means a closed system, where patients phase in 
and out due to moving or switching insurances, or have prescriptions filled outside the 
EHR. If they had been on a drug prior to their AMI but the drug exposure was not 
captured by the clinical database, we would under-estimate the log risk ratio (associated 
with false negatives). 
 Second, the success of using a patient’s experience of AMI during the not-at-risk 
periods as his own reference is contingent on a key assumption that confounding 
covariates are time-invariant. Some covariates are certainly time-invariant, e.g., sex and 
race; however, age is not if age is indeed a confounder. It is possible to adjust for time-
varying covariates in the estimation of risk ratio with by adding age as a covariate in the 
SCCS (Whitaker HJ, Farrington CP [45]).   
 Third, a patient’s risk for an outcome may not be constant but diminish over time 
with continued use of a drug. The SCCS method may be more sensitive if the analysis is 
restricted to new users, and to immediate periods (duration is drug-dependent) rather than 
the entire observation period (defined as the entire period that a patient has been under 
observation in an EHR or the enrollment period for claims). 
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 As most adverse drug events have low incidence, it usually requires a large 
number of subjects with exposure to the drug for the detection of these events with a 
sufficient statistical power. Thus, it is critical to develop efficient methods to detect 
signals as early and reliably as possible so that proper actions can be taken to avoid the 
occurrence of more events. Conventional analytical strategies that utilize only the data 
from the drug of interest for statistical evaluation are not efficient from this perspective. 
The empirical Bayes approach described in this article offers an objective, more efficient, 
and easily interpretable solution to this problem. 
 The estimation of the prior distribution is of interest for two main reasons. Firstly, 
we want to learn the ensemble properties such as Pr(𝑅𝑅 > 2), which is an important 
metric to compute the number of drugs with strong associations with an adverse event. 
Secondly, we want to get the posterior distribution through empirical Bayes calculations, 
for instance, Pr(𝑅𝑅 > 2|𝑅?̂?∗ = 2.19, 𝜎∗ = 0.345). Compared with nonparametric 
methods from Laird [51], Fan [52], Hall and Meister [53] and Butucea and Comte [54], 
the Bayes deconvolution method we use here strikes a balance between convergence rate 
and robustness: the estimation has a root-N convergence rate and the class of the prior 
distributions as represented by splines is rich enough so it should be adequate for most 
practical applications. Accurate estimation of the prior distribution requires sufficient 
number of drugs. As shown in Table 23 and Table 24, there is some level of variations in 
the estimates of the prior/posterior quantities due to relatively limited number of drugs. 
As more and more data are accumulating in EHRs, more drugs may be included such that 
the variations can be substantially reduced to a level that is negligible. Thus, we believe 
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that our empirical Bayes approach holds strong potential for future post-marketing safety 
surveillance.  
 
4.6 Conclusion 
 Bias correction can be used to improve inference accuracy for drug-outcome 
associations. The distribution of 𝑅𝑅 estimated through a large set of drug-outcome risk 
estimates provides an informative description of the state of drug-outcome associations 
and is readily useful for an empirical Bayes inference of the association for an individual 
drug-outcome pair.  
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APPENDIX A PROOF OF ASYMPTOTIC NORMALITY AND 
CONSISTENCY OF ?̂?𝑀𝑅   
 We first prove asymptotic normality and then prove consistency. 
 By definition 
?̂?𝑀𝑅 ≡ 𝜓𝑀𝑅(?̅?; ?̂?𝐷(?̂?, ?̂?), ?̂?𝐷(𝛾, ?̂?), 𝛾, ?̂?) 
Let ?̂? ≡ (?̂?𝐷(?̂?, ?̂?)
𝑇 , ?̂?𝐷(?̂?, ?̂?)
𝑇 , 𝛾𝑇 , ?̂?𝑇)𝑇 denote the vector of nuisance parameter 
estimates and 𝛽∗ ≡ (𝛼∗,𝑇, 𝜂∗,𝑇 , 𝛾∗𝑇 , 𝜔∗,𝑇)𝑇 denote the limit of ?̂?.  If model (iii) for Pr (𝑅 =
1|𝑌, 𝐴, 𝐗) is correct, then 𝛾∗ is the true value 𝛾0. If model (iv) for Pr (𝑍 = 1|𝑅 =
1, 𝑌, 𝐴, 𝐗) or 𝐸(𝑍|𝑅 = 1 , 𝑌, 𝐴, 𝑋) is correct, then 𝜔∗ is the true value 𝜔0.  By the double 
robustness property of ?̂?𝐷(?̂?, ?̂?), if either model (iii) and model (iv) is correct, and model 
(i) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] is also correct, then 𝜂∗ is the true value 𝜂0. Similarly, by the double 
robustness property of ?̂?𝐷(𝛾, ?̂?), if either model (iii) and model (iv) is correct, and model 
(ii) for Pr(𝐴 = 1|𝐗, 𝑍)is also correct, then 𝛼∗ is the true value 𝛼0.  
 Let 𝑆𝛼(𝐴, 𝐗, 𝑍), 𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍), 𝑆𝛾(𝑅, 𝑌, 𝐴, 𝐗), and 𝑆𝜔(𝑌, 𝐴, 𝐗, 𝑍) denote the score 
functions for the imposed working models 𝑒(𝐗, 𝑍; 𝛼), 𝑏(𝐴, 𝐗, 𝑍; 𝜂), 𝜋(𝑌, 𝐴, 𝐗; 𝛾), and 
𝜛(𝑌, 𝐴, 𝐗; 𝜔) respectively. Simple algebra leads to the following estimating equations 
(applying DR to the estimation of 𝛼 and 𝜂): 
0 = P𝑛𝑄(𝐎; ?̂?) ≡ P𝑛
{
 
 
 
 
 
 
 
 
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
𝑆𝛼(𝐴, 𝐗, 𝑍; ?̂?𝐷(𝛾, ?̂?)) + (1 −
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
)
× 𝐸[𝑆𝛼(𝐴, 𝐗, 𝑍; ?̂?𝐷(𝛾, ?̂?))|𝑅 = 1, 𝑌, 𝐴, 𝐗; ?̂?]
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍; ?̂?𝐷(𝛾, ?̂?)) + (1 −
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾)
)
× 𝐸[𝑆𝜂(𝑌, 𝐴, 𝐗, 𝑍; ?̂?𝐷(𝛾, ?̂?))|𝑅 = 1, 𝑌, 𝐴, 𝐗; ?̂?]
𝑆𝛾(𝑅, 𝑌, 𝐴, 𝐗; 𝛾)
𝑆𝜔(𝑌, 𝐴, 𝐗, 𝑍; ?̂?) }
 
 
 
 
 
 
 
 
 
Under suitable regularity conditions as stated in [16, 55, 56] 
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√𝑛(?̂? − 𝛽∗) = √𝑛P𝑛 {[𝐸 (−
𝜕𝑄(𝐎;𝛽∗)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎;𝛽∗)} + 𝑜𝑝(1). 
By Taylor expansion, we have 
√𝑛(?̂?𝑀𝑅 − 𝜓
∗) = √𝑛(𝜓𝑀𝑅(?̅?; 𝛽
∗) − 𝜓∗) +
𝜕𝜓𝑀𝑅(?̅?;𝛽
∗)
𝜕𝛽𝑇
√𝑛(?̂? − 𝛽∗) + 𝑜𝑝(1), 
where 𝜓∗ = 𝐸[𝜓𝑀𝑅(?̅?; 𝛽
∗)]. We could prove that 𝜓∗ = 𝜓0 if one of the four conditions 
from Section 0 holds. (Include more details) 
 Let 𝜓𝑀𝑅(?̅?; 𝛽) = P𝑛{𝜑𝑀𝑅(𝐎; 𝛽)}. Thus,  
√𝑛(?̂?𝑀𝑅 − 𝜓
∗)
= √𝑛P𝑛{𝜑𝑀𝑅(𝐎; 𝛽
∗) − 𝜓∗}
+
𝜕𝜓𝑀𝑅(?̅?; 𝛽
∗)
𝜕𝛽𝑇
(√𝑛P𝑛 {[𝐸 (−
𝜕𝑄(𝐎;𝛽∗)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎; 𝛽∗)} + 𝑜𝑝(1))
+ 𝑜𝑝(1)
= √𝑛P𝑛{𝜑𝑀𝑅(𝐎; 𝛽
∗) − 𝜓∗}
+ 𝐸 [
𝜕𝜑𝑀𝑅(𝐎; 𝛽
∗)
𝜕𝛽𝑇
]√𝑛P𝑛 {[𝐸 (−
𝜕𝑄(𝐎;𝛽∗)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎; 𝛽∗)} + 𝑜𝑝(1)
= √𝑛P𝑛 {𝜑𝑀𝑅(𝐎; 𝛽
∗) − 𝜓∗
+ 𝐸 [
𝜕𝜑𝑀𝑅(𝐎; 𝛽
∗)
𝜕𝛽𝑇
] [𝐸 (−
𝜕𝑄(𝐎;𝛽∗)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎; 𝛽∗)} + 𝑜𝑝(1) 
By Central Limit Theorem, √𝑛(?̂?𝑀𝑅 − 𝜓
∗) → 𝑁(0, Σ), where 
Σ = 𝐸 [𝜑𝑀𝑅(𝐎; 𝛽
∗) − 𝜓∗ + 𝐸 [
𝜕𝜑𝑀𝑅(𝐎; 𝛽
∗)
𝜕𝛽𝑇
] [𝐸 (−
𝜕𝑄(𝐎; 𝛽∗)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎;𝛽∗)]
2
. 
The covariance matrix Σ can be estimated by  
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Σ̂ = P𝑛 {(𝜑𝑀𝑅(𝐎; ?̂?) − ?̂?𝑀𝑅 + P𝑛 [
𝜕𝜑𝑀𝑅(𝐎; ?̂?)
𝜕𝛽𝑇
] [P𝑛 (−
𝜕𝑄(𝐎; ?̂?)
𝜕𝛽𝑇
)]
−1
𝑄(𝐎; ?̂?))
2
} 
 Next, we prove consistency, i.e., 𝜓∗ = 𝜓0 if one of conditions 1-4 listed in 
Section 0 holds. Note that 𝜓∗ = 𝜇1
∗ − 𝜇0
∗ , where for 𝑎 ∈ {0,1} and 𝑓𝐴(𝑎, 𝐗, 𝑍; 𝛼) =
𝑒(𝐗, 𝑍; 𝛼)𝐴(1 − 𝑒(𝐗, 𝑍; 𝛼))
1−𝐴
, we define 
𝜇𝑎
∗
= 𝐸 [
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾∗)
(
𝐼(𝐴 = 𝑎)
𝑓𝐴(𝑎, 𝐗, 𝑍; 𝛼∗)
𝑌 − (
𝐼(𝐴 = 𝑎)
𝑓𝐴(𝑎, 𝐗, 𝑍; 𝛼∗)
− 1) 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂∗))]
− 𝐸 [(
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾∗)
− 1)
× 𝐸 [(
𝐼(𝐴 = 𝑎)
𝑓𝐴(𝑎, 𝐗, 𝑍; 𝛼∗)
− (
𝐼(𝐴 = 𝑎)
𝑓𝐴(𝑎, 𝐗, 𝑍; 𝛼∗)
− 1) 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂∗)) |𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔∗]] 
Without loss of generality, we prove that  𝜇1
∗ = 𝐸[𝑌𝑎=1] under conditional 1 in which 
model (i) for 𝐸[𝑌|𝐴, 𝐗, 𝑍] and model (iii) for Pr (𝑅 = 1|𝑌, 𝐴, 𝐗) are correct. Similar 
arguments can be made for other conditions, and then for 𝜇0
∗  and thus 𝜓∗ under all 4 
conditions. 
 As explained above, when models (i) and (iii) are correct, 𝜂∗ = 𝜂0 and 𝛾
∗ = 𝛾0, 
then 
𝜇1,𝑀𝑅(𝛽
∗) 
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= 𝐸 [
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾0)
(
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
𝑌 − (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
− 1) 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0))]
− 𝐸 [(
𝑅
𝜋(𝑌, 𝐴, 𝐗; 𝛾0)
− 1)
× 𝐸 [(
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
− (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
− 1) 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0)) |𝑅 = 1, 𝑌, 𝐴, 𝐗; 𝜔
∗]] 
The second expectation is zero because 𝐸 [(
𝑅
𝜋(𝑌,𝐴,𝐗;𝛾0)
− 1) |𝑌, 𝐴, 𝑋] =
𝜋(𝑌,𝐴,𝐗;𝛾0)
𝜋(𝑌,𝐴,𝐗;𝛾0)
− 1 = 0. 
 Note that under MAR, 𝐸[𝑅|𝑌, 𝐴, 𝐗, 𝑍] = 𝐸[𝑅|𝑌, 𝐴, 𝐗] =  𝜋(𝑌, 𝐴, 𝐗; 𝛾0), thus the 
first expectation equals 
 𝐸 [
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
𝑌 − (
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
− 1)𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0)]
= 𝐸 [
𝐼(𝐴 = 1)
𝑒(𝐗, 𝑍; 𝛼∗)
(𝑌 − 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0)) + 𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0)]
= 𝐸[𝑏(𝐴 = 1, 𝐗, 𝑍; 𝜂0)] = 𝐸[𝐸[𝑌|𝐴 = 1, 𝐗, 𝑍]] = 𝐸[𝐸[𝑌1|𝐴 = 1, 𝐗, 𝑍]]
= 𝐸[𝐸[𝑌1|𝐗, 𝑍]] = 𝐸[𝑌1] 
The second to last equality holds because of the assumption of no unmeasured 
confounding.  The third to last equality holds because of the consistency assumption. 
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APPENDIX B AN EMPIRICAL VARIANCE ESTIMATE OF ?̂?𝑎  
WITH BINARY MISSING COVARIATE 𝑍 
Assumptions: 
A.1 Up to one from each of the two pairs of models (propensity and outcome regression, 
missing probability and 𝜛 = 𝑓(𝑍 = 1|𝑌, 𝐴, 𝑋) may be wrong so that ?̂?𝑎 is still 
consistent.  
A.2 For models that are wrong, the parameter estimator converges to some value and is 
asymptotically normal. 
We will use the same notation of 𝜃 = (𝛼, 𝜂, 𝜍, 𝛾) to annotate the value the estimators 
converge to, with the understanding that values corresponding to the wrong models might 
not have clear meaning.  
First note that for logistic regression:  
logit[Pr(𝑌 = 1|𝑋)] = logit(𝑝𝑋) = 𝑋
𝑇𝛽 
The score function is 
𝑆𝛽(𝑌) = 𝑋(𝑌 − 𝑝𝑋) 
 Let 𝐸∗ be the expectation with respect to 𝑓(𝑍 = 1|𝑅 = 1, 𝑌, 𝐴, 𝑋). Based on Lingling's 
derivation: 
∂?̂?𝑎
∂𝜍
= −𝐏𝑛 (
𝑅
𝜋2
∂𝜋
∂𝜍
(𝑀𝑎 − 𝐸∗(𝑀𝑎))) = −𝐏𝑛 (
𝑅
𝜋
(𝑀𝑎 − 𝐸∗(𝑀𝑎))𝑆𝜍(1)) 
∂?̂?𝑎
∂𝛾
= −𝐏𝑛 ((
𝑅
𝜋
− 1)𝐸∗(𝑀𝑎𝑆𝛾(1))) 
∂?̂?𝑎
∂𝛼
= −𝐏𝑛 (
𝑅𝐼(𝐴 = 𝑎)
𝜋𝑒𝑎
(𝑌 − 𝑏𝑎)𝑆𝛼(𝑎) + (1 −
𝑅
𝜋
) 𝐼(𝐴 = 𝑎)𝐸∗ (
(𝑌 − 𝑏𝑎)
𝑒𝑎
𝑆𝛼(𝑎))) 
∂?̂?𝑎
∂𝜂
= −𝐏𝑛 (
𝑅
𝜋
(
𝐼(𝐴 = 𝑎)
𝑒𝑎
− 1)𝑏𝑎𝑆𝜂(𝑎) + (1 −
𝑅
𝜋
)𝐸∗ [(
𝐼(𝐴 = 𝑎)
𝑒𝑎
− 1) 𝑏𝑎𝑆𝜂(𝑎)]) 
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Let 𝐶• be the covariate vector associated with • (•= 𝛼, 𝜂, 𝜍, 𝛾). The estimators (?̂?, ?̂?, 𝜍̂, 𝛾) 
are determined by the following estimating equations: 
𝐏𝑛𝑄 = 𝐏𝑛(
𝑄1(𝛼, 𝜍, 𝛾)
𝑄2(𝜂, 𝜍, 𝛾)
𝑄3(𝜍)
𝑄4(𝛾)
) = 𝐏𝑛
(
 
 
 
 
(
𝑅
𝜋
(𝐴 − 𝑒1)𝐶𝛼 + (1 −
𝑅
𝜋
)𝐸∗[(𝐴 − 𝑒1)𝐶𝛼])
(
𝑅
𝜋
(𝑌 − 𝑏)𝐶𝜂 + (1 −
𝑅
𝜋
)𝐸∗[(𝑌 − 𝑏)𝐶𝜂])
(𝑅 − 𝜋)𝐶𝜍
(𝑍 − 𝜛)𝐶𝛾 )
 
 
 
 
= 0 
Under regularity conditions, 
√𝑛(𝜃 − 𝜃) = √𝑛(
?̂? − 𝛼
?̂? − 𝜂
𝜍̂ − 𝜍
𝛾 − 𝛾
) =
1
√𝑛
Σ𝑛 [𝐸 (−
∂𝑄
∂𝜃𝑇
)]
−1
𝑄 + 𝑜𝑝(1) (Σ𝑛 indicate summation 
over the 𝑛 records) 
∂𝑄1
∂𝜃𝑇
=
(
 
 −(
𝑅
𝜋
𝑒1𝐶𝛼𝑆𝛼
𝑇(1) + (1 −
𝑅
𝜋
)𝐸∗(𝑒1𝐶𝛼𝑆𝛼
𝑇(1))) , 0,
−
𝑅
𝜋
((𝐴 − 𝑒1)𝐶𝛼 − 𝐸∗((𝐴 − 𝑒1)𝐶𝛼))𝑆𝜍
𝑇(1), (1 −
𝑅
𝜋
)𝐸∗[(𝐴 − 𝑒1)𝐶𝛼𝑆𝛾
𝑇(1)]
)
 
 
 
∂𝑄2
∂𝜃𝑇
= (
0,− (
𝑅
𝜋
𝑏𝐶𝜂𝑆𝜂
𝑇(1) + (1 −
𝑅
𝜋
)𝐸∗(𝑏𝐶𝜂𝑆𝜂
𝑇(1))) ,
−
𝑅
𝜋
((𝑌 − 𝑏)𝐶𝜂 − 𝐸∗((𝑌 − 𝑏)𝐶𝜂)𝑆𝜍
𝑇(1), (1 −
𝑅
𝜋
)𝐸∗[(𝑌 − 𝑏)𝐶𝜂𝑆𝛾
𝑇(1)]
) 
∂𝑄3
∂𝜃𝑇
= (0,0, −𝜋𝐶𝜍𝑆𝜍
𝑇(1),0) 
∂𝑄4
∂𝜃𝑇
= (0,0,0,−𝜛𝐶𝛾𝑆𝛾
𝑇(1)) 
Based on Taylor expansion 
√𝑛 (?̂?𝑎(𝜃) − 𝐸(𝑌𝑎)) 
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= √𝑛(?̂?𝑎 (𝜃) − 𝐸(𝑌𝑎)) +
𝜕?̂?𝑎
𝜕𝛼𝑇 
 √𝑛(?̂? − 𝛼) +
𝜕?̂?𝑎
𝜕𝜂𝑇
√𝑛(?̂? − 𝜂) +
𝜕?̂?𝑎
𝜕𝜍𝑇
 √𝑛(𝜍̂ − 𝜍)
+
𝜕?̂?𝑎
𝜕𝛾𝑇
 √𝑛(?̂? − 𝛾) + 𝑜𝑝 (1) 
Let ?̂?𝑎 = 𝑃𝑛 ?̂?𝑎 
=
1
√n
Σn(?̂?a(θ) − E(Ya)) + (
∂φ̂a
∂αT
,
∂φ̂a
∂ηT
,
∂φ̂a
∂ςT
,
∂φ̂a
∂γT
) (
1
√n
Σn [E (−
∂Q
∂θT
)]
−1
Q + op(1)) 
=
1
√n
Σn(?̂?a(θ) − E(Ya)) + E(
∂?̂?a
∂αT
,
∂?̂?a
∂ηT
,
∂?̂?a
∂ςT
,
∂?̂?a
∂γT
)
1
√n
Σn [E (−
∂Q
∂θT
)]
−1
Q + op(1) 
=
1
√n
Σn [?̂?a(θ) − E(Ya) + E(
∂?̂?a
∂αT
,
∂?̂?a
∂ηT
,
∂?̂?a
∂ςT
,
∂?̂?a
∂γT
) [E (−
∂Q
∂θT
)]
−1
Q] + op(1) 
By CLT, the asymptotic variance of ?̂?𝑎 (𝜃) can be estimated as 
𝑉𝑎?̂? (?̂?𝑎 (𝜃)) =
1
𝑛
𝑃𝑛 [?̂?𝑎 (𝜃) − ?̂?𝑎 (𝜃)
+ [(
𝜕?̂?𝑎
𝜕𝛼𝑇
,
𝜕?̂?𝑎
𝜕𝜂𝑇
,
𝜕?̂?𝑎
𝜕𝜍𝑇
,
𝜕?̂?𝑎
𝜕𝛾𝑇
) (𝑃𝑛 (−
𝜕𝑄
𝜕𝜃𝑇
))
−1
 ] |𝜃=?̂? 𝑄]
2
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APPENDIX C AN EMPIRICAL VARIANCE ESTIMATE OF ?̂?𝑎  
WITH CONTINUOUS MISSING COVARIATE 𝑍 
 For the situation of continuous missing covariate, we substituted  ?̂? for Z in the 
expectation part (for dealing with treatment effects). Thus, the estimator was as 
following: 
?̂?𝑎 =
𝑅
𝜋
𝑀𝑎 − (
𝑅
𝜋
− 1)𝐸∗(𝑀𝑎) 
where 𝑀𝑎 =
𝐴𝑎
𝑒𝑎
𝑌 − (
𝐴𝑎
𝑒𝑎
− 1) 𝑏𝑎, 𝐸∗(𝑀𝑎) =
𝐴𝑎
?̂?𝑎
𝑌 − (
𝐴𝑎
?̂?𝑎
− 1) ?̂?𝑎. 𝐴𝑎 = 𝐼(𝐴 = 𝑎). 
For 𝑒?̂? = Pr(𝐴 = 1|𝑋, ?̂?) = 𝑒𝑥𝑝𝑖𝑡(𝛼0 + 𝛼1𝑋 + 𝛼2 ?̂?) = 𝑒𝑥𝑝𝑖𝑡[(𝛼2𝛾0 + 𝛼2𝛾1𝑌 +
 𝛼2𝛾2𝐴 + 𝛼2𝛾3𝑋) + 𝛼0 + 𝛼1𝑋]. We set 𝑋
′ = 𝛼2(1 𝑌 𝐴 𝑋)
′, 𝜃 = 𝛼0 + 𝛼1𝑋 which was 
not related to 𝛾. Then ?̂?𝑎 = 𝑒𝑥𝑝𝑖𝑡(𝑋
′𝛾 + 𝜃) =
exp(𝑋′𝛾+𝜃)
1+exp(𝑋′𝛾+𝜃)
. 
𝑙𝐴(𝛾) = 𝐴 log
?̂?𝑎
1 − ?̂?𝑎
+ log(1 − ?̂?𝑎)
= 𝐴(𝑋′𝛾 + 𝜃) − log[1 − exp(𝑋′𝛾 + 𝜃)] 
So we had ?̂?𝛾,𝐴(𝐴) =
𝜕𝑙𝐴
𝜕𝛾
= 𝑋′(𝐴 − ?̂?𝑎). 
𝜕𝑒?̂?
𝜕𝛾
=
𝑋′ exp(𝑋′𝛾 + 𝜃)
(1 + exp(𝑋′𝛾 + 𝜃))2
= 𝑋′?̂?𝑎(1 − ?̂?𝑎) = ?̂?𝑎?̂?𝛾,𝐴(1) 
Similarly, ?̂?𝑎 = Pr(𝑌 = 1|𝐴, 𝑋, ?̂?) = 𝑒𝑥𝑝𝑖𝑡(𝜂0 + 𝜂1𝐴 + 𝜂2𝑋 + 𝜂3 ?̂?) 
= 𝑒𝑥𝑝𝑖𝑡[(𝜂3𝛾0 + 𝜂3𝛾1𝑌 + 𝜂3𝛾2𝐴 + 𝜂3𝛾3𝑋) + 𝜂0 + 𝜂1𝐴 + 𝜂2𝑋] 
We set 𝑋′′ = 𝜂3(1 𝑌 𝐴 𝑋)
′, θ′ = η0 + η1A + η2X. We had Ŝγ,Y(Y) = X′′(Y − b̂a), 
∂b̂a
∂γ
=
b̂aŜγ,Y(1). 
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𝜕?̂?𝑎
𝜕𝜁
= −𝑃𝑛 [
𝑅
𝜋2
𝜕𝜋
𝜕𝜁
(𝑀𝑎 − 𝐸∗(𝑀𝑎))] = −𝑃𝑛 [
𝑅
𝜋
(𝑀𝑎 − 𝐸∗(𝑀𝑎))𝑆𝜁(1)] 
= −𝑃𝑛 [
𝑅
𝜋
(𝑀𝑎 − 𝐸∗(𝑀𝑎))(1 − 𝜋)(1 𝑌 𝐴 𝑋)′] 
𝜕?̂?𝑎
𝜕𝛾
= −𝑃𝑛 [(
𝑅
𝜋
− 1)
𝜕𝐸∗(𝑀𝑎)
𝜕𝛾
] = −𝑃𝑛 [(
𝑅
𝜋
− 1)
𝜕
𝜕𝛾
( 
𝐴𝑎
?̂?𝑎
( 𝑌 − ?̂?𝑎) + ?̂?𝑎)] 
= −𝑃𝑛 [(
𝑅
𝜋
− 1)(−
𝐴𝑎
?̂?𝑎
( 𝑌 − ?̂?𝑎)?̂?𝛾,𝐴(1) −
𝐴𝑎
?̂?𝑎
?̂?𝑎?̂?𝛾,𝑌(1) + ?̂?𝑎?̂?𝛾,𝑌(1))] 
= −𝑃𝑛 [(
𝑅
𝜋
− 1)(−
𝐴𝑎
?̂?𝑎
( 𝑌 − ?̂?𝑎)?̂?𝛾,𝐴(1) + (1 −
𝐴𝑎
?̂?𝑎
) ?̂?𝑎?̂?𝛾,𝑌(1))] 
= −𝑃𝑛 [(1 −
𝑅
𝜋
)(
𝐴𝑎
?̂?𝑎
( 𝑌 − ?̂?𝑎)?̂?𝛾,𝐴(1) + (
𝐴𝑎
?̂?𝑎
− 1) ?̂?𝑎?̂?𝛾,𝑌(1))] 
= −𝑃𝑛 [(1 −
𝑅
𝜋
)(
𝐴𝑎
?̂?𝑎
( 𝑌 − ?̂?𝑎)𝛼2(1 𝑌 𝐴 𝑋)
′(𝑎 − ?̂?𝑎)
+ (
𝐴𝑎
?̂?𝑎
− 1) ?̂?𝑎𝜂3(1 𝑌 𝐴 𝑋)
′(1 − ?̂?𝑎))] 
𝜕?̂?𝑎
𝜕𝛼
= 𝑃𝑛 [
𝜕
𝜕𝛼
(
𝑅
𝜋
𝐴𝑎
𝑒𝑎
(𝑌 − 𝑏𝑎) + (1 −
𝑅
𝜋
)
𝐴𝑎
?̂?𝑎
(𝑌 − ?̂?𝑎))] 
= −𝑃𝑛 [
𝑅
𝜋
𝐴𝑎
𝑒𝑎
(𝑌 − 𝑏𝑎)𝑆𝛼(𝑎) + (1 −
𝑅
𝜋
)
𝐴𝑎
?̂?𝑎
(𝑌 − ?̂?𝑎)?̂?𝛼(𝑎)] 
= −𝑃𝑛 [
𝑅
𝜋
𝐴𝑎
𝑒𝑎
(𝑌 − 𝑏𝑎)(1 𝑋 𝑍)
′(𝑎 − 𝑒𝑎) + (1 −
𝑅
𝜋
)
𝐴𝑎
?̂?𝑎
(𝑌 − ?̂?𝑎)(1 𝑋 ?̂?)
′
(𝑎 − ?̂?𝑎)] 
 
𝜕?̂?𝑎
𝜕𝜂
= 𝑃𝑛 [
𝜕
𝜕𝜂
(
𝑅
𝜋
(1 −
𝐴𝑎
𝑒𝑎
) 𝑏𝑎 + (1 −
𝑅
𝜋
)(1 −
𝐴𝑎
?̂?𝑎
) ?̂?𝑎)] 
= −𝑃𝑛 [
𝑅
𝜋
(
𝐴𝑎
𝑒𝑎
− 1)𝑏𝑎𝑆𝜂
𝑎(1) + (1  −
𝑅
𝜋
) (
𝐴𝑎
?̂?𝑎
− 1) ?̂?𝑎?̂?𝜂
𝑎 (1)] 
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= −𝑃𝑛 [
𝑅
𝜋
(
𝐴𝑎
𝑒𝑎
− 1)𝑏𝑎(1 𝑎 𝑋 𝑍)′(1 − 𝑏𝑎) + (1 −
𝑅
𝜋
)(
𝐴𝑎
?̂?𝑎
− 1) ?̂?𝑎(1 𝑎 𝑋 ?̂?)′(1 − ?̂?𝑎)] 
The estimators (?̂?, ?̂?, 𝜁, 𝛾)
′
 were determined by the following equations: 
𝑃𝑛𝑄 = 𝑃𝑛 (
𝑄1(𝛼, 𝜁, 𝛾)
𝑄2(𝜂, 𝜁, 𝛾)
𝑄3(𝜁)
𝑄4(𝛾)
) = 𝑃𝑛
(
 
 
 
 
𝑅
𝜋
(𝐴 − 𝑒1)𝐶𝛼 + (1 −
𝑅
𝜋
)𝐸∗[(𝐴 − 𝑒1)𝐶𝛼]
𝑅
𝜋
(𝑌 − 𝑏)𝐶𝜂 + (1 −
𝑅
𝜋
)𝐸∗[(𝑌 − 𝑏)𝐶𝜂]
(𝑅 − 𝜋)𝐶𝜁
𝑅(𝑍 − ?̂?)𝐶𝛾 )
 
 
 
 
= 0 
 Therefore, we have: 
𝜕𝑄1
𝜕𝜃𝑇
= (−(
𝑅
𝜋
𝑒1𝐶𝛼𝑆𝛼
𝑇(1) + (1 −
𝑅
𝜋
)𝐸∗[𝑒1𝐶𝛼𝑆𝛼
𝑇(1)]) , 𝟎, −
𝑅
𝜋
((𝐴 − 𝑒1)𝐶𝛼 −
𝐸∗[(𝐴 − 𝑒1)𝐶𝛼])𝑆𝜁
𝑇(1), (1 −
𝑅
𝜋
 ) (−?̂?1?̂?𝛼?̂?𝛾,𝐴(1) + (𝐴 − ?̂?1) (
𝟎
𝟎
𝐶𝛾
𝑇
)))  
𝜕𝑄2
𝜕𝜃𝑇
= (𝟎,− (
𝑅
𝜋
𝑏𝐶𝜂𝑆𝜂
𝑇(1) + (1 −
𝑅
𝜋
)𝐸∗[𝑏𝐶𝜂𝑆𝜂
𝑇(1)]) , −
𝑅
𝜋
((𝑌 − 𝑏)𝐶𝜂 − 𝐸∗[(𝑌 −
𝑏)𝐶𝜂]) 𝑆𝜁
𝑇(1), (1 −
𝑅
𝜋
 ) (−?̂??̂?𝜂?̂?𝛾,𝑌(1) + (𝑌 − ?̂?) (
𝟎
𝟎
𝐶𝛾
𝑇
)))  
𝜕𝑄3
𝜕𝜃𝑇
= (𝟎, 𝟎, −𝜋𝐶𝜁𝑆𝜁
𝑇(1), 𝟎)  
𝜕𝑄4
𝜕𝜃𝑇
= (𝟎, 𝟎, 𝟎, −𝑅?̂?𝐶𝛾𝐶𝛾
𝑇  ). 
 By CLT and Taylor expansion, the asymptotic variance of ?̂?𝑎(𝜃) can be 
estimated as: 
𝑉𝑎?̂? (?̂?𝑎(𝜃)) = 𝑃𝑛 {(?̂?𝑎(𝜃) − ?̂?𝑎(𝜃) + 𝑃𝑛 (
𝜕?̂?𝑎
𝜕𝛼𝑇
,
𝜕?̂?𝑎
𝜕𝜂𝑇
,
𝜕?̂?𝑎
𝜕𝜁𝑇
,
𝜕?̂?𝑎
𝜕𝛾𝑇
) [𝑃𝑛 (−
𝜕𝑄
𝜕𝜃𝑇
)]
−1
𝑄)
2
} 
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APPENDIX D OMOP ADJUDICATED LIST OF DRUGS POSITIVELY AND 
NEGATIVELY ASSOCIATED WITH AMI 
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APPENDIX E BAYES DECONVOLUTION 
We applied the MLE to obtain ?̂?(𝛿) and (?̂?1, ?̂?2), where the sample space of 𝛿 is 
discretized at (𝛿1, … , 𝛿𝑚) with grid precision 0.01[57]. Since 𝜎 and 𝛿 are independent, 
the estimated distribution of 𝜃 given 𝜎 is 
 ?̂?(𝜃|𝜎) = ?̂?[𝜃 − (?̂?1𝜎 + ?̂?2𝜎
2)]. (18)  
 Consequently,  
 ?̂?(𝜃) =
1
𝑁
∑?̂?(𝜃|𝜎𝑖)
𝑁
𝑖=1
=
1
𝑁
∑?̂?[𝜃 − (?̂?1𝜎𝑖 + ?̂?2𝜎𝑖
2)]
𝑁
𝑖=1
 
(19)  
Based on ?̂?(𝛿), we employ Bayes rule to estimate the posterior distribution for a new 
drug with (𝑅?̂?∗, 𝜎∗). Let 𝜃∗ = log𝑅?̂?∗. Then 
 
?̂?(𝜃|𝜃∗, 𝜎∗) 
=
Pr(𝜃∗|𝜃, 𝜎∗) ⋅ ?̂?(𝜃|𝜎∗)
∑ Pr(𝜃∗|𝜃𝑗 , 𝜎∗) ⋅ ?̂?(𝜃𝑗|𝜎
∗)𝑚𝑗=1
 
= 
𝛷(
𝜃∗ − 𝜃
𝜎∗ ) ⋅ ?̂? (𝜃 − (?̂?1𝜎
∗ + ?̂?2(𝜎
∗)2))
∑ 𝛷(
𝜃 − 𝜃𝑗
𝜎∗ ) ⋅ ?̂? (𝜃𝑗 − (?̂?1𝜎
∗ + ?̂?2(𝜎∗)2))
𝑚
𝑗=1
 
(20)  
Here 𝜃𝑗 = 𝛿𝑗 + ?̂?1𝜎
∗ + ?̂?2(𝜎
∗)2, 𝑗 = 1,… ,𝑚, based on the 𝛿’s grid (𝛿1, … , 𝛿𝑚). Based on 
?̂?(𝜃) and ?̂?(𝜃|𝜃 ̂∗, 𝜎∗), ?̂?(𝑅𝑅) and ?̂?(𝑅𝑅|𝑅?̂?∗, 𝜎∗) can be derived through variable 
transformation.  
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